<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title>Frontiers in Neurology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurol.</abbrev-journal-title>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fneur.2017.00630</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Role of Hyperintense Acute Reperfusion Marker for Classifying the Stroke Etiology</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Choi</surname> <given-names>Hee Young</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lee</surname> <given-names>Kyung Mi</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x0002A;</xref>
<uri xlink:href="http://frontiersin.org/people/u/440862"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname> <given-names>Hyug-Gi</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/471255"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname> <given-names>Eui Jong</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Choi</surname> <given-names>Woo Suk</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname> <given-names>Bum Joon</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/470982"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Heo</surname> <given-names>Sung Hyuk</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/387515"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Chang</surname> <given-names>Dae-Il</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Radiology, Kyung Hee University College of Medicine, Kyung Hee University Hospital</institution>, <addr-line>Seoul</addr-line>, <country>South Korea</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Neurology, Kyung Hee University College of Medicine, Kyung Hee University Hospital</institution>, <addr-line>Seoul</addr-line>, <country>South Korea</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Bruce Campbell, University of Melbourne, Australia</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Henry Ma, Monash University, Australia; Felix Ng, Austin Health, Australia</p></fn>
<corresp content-type="corresp" id="cor1">&#x0002A;Correspondence: Kyung Mi Lee, <email>bandilee&#x00040;khu.ac.kr</email></corresp>
<fn fn-type="other" id="fn001"><p>Specialty section: This article was submitted to Stroke, a section of the journal Frontiers in Neurology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>29</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>630</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>08</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>11</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2017 Choi, Lee, Kim, Kim, Choi, Kim, Heo and Chang.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Choi, Lee, Kim, Kim, Choi, Kim, Heo and Chang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract abstract-type="executive-summary">
<sec id="ST1">
<title>Purpose</title>
<p>The hyperintense acute reperfusion marker (HARM) is a delayed enhancement of the subarachnoid or subpial space observed on post-contrast fluid-attenuated inversion recovery (FLAIR) images and is associated with permeability changes to the blood&#x02013;brain barrier in acute stroke. We investigated the relationship between HARM and stroke etiology based on the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification. In addition, we evaluated the relationship between HARM and stroke locations with respect to vascular territories and anatomic compartments.</p>
</sec>
<sec id="ST2">
<title>Materials and methods</title>
<p>We recruited 264 consecutive patients (109 women; mean age 68.63&#x02009;years) who were diagnosed with acute ischemic stroke and underwent brain magnetic resonance imaging (MRI) including post-contrast FLAIR and DWI within 7&#x02009;days of symptom onset from May 2015 to March 2016 for this retrospective study. Post-contrast FLAIR images were obtained 5&#x02009;min after gadolinium administration. The mean time interval between the onset of stroke symptoms and MRI acquisition in total included patients was 18&#x02009;h and 7&#x02009;min (median 12&#x02009;h and 57&#x02009;min, range 2&#x02013;127&#x02009;h). We analyzed the overall incidence and distribution patterns of HARM in acute ischemic stroke cases and compared the relative incidence and distribution patterns of HARM between the subgroups of stroke etiology based on conventional TOAST classification. We obtained odds ratio (OR) of HARM in different stroke locations based on vascular territories and anatomical compartments. This study was approved by our institutional review board.</p>
</sec>
<sec id="ST3">
<title>Results</title>
<p>Among the 264 patients, 67 (25.38%) patients were HARM positive and 197 (74.62%) patients were HARM negative. There was significant difference in HARM incidence among the stroke subgroups (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001). Small vessel occlusion (SVO) was associated with the HARM-negative group (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001), while large artery atherosclerosis (LAA) and cardioembolism (CE) were associated with the HARM-positive group (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.001). Also, regional pattern of HARM on the same vascular territory as the acute infarction was dominantly demonstrated regardless of stroke etiology. The OR for HARM from middle cerebral artery (MCA) infarction was 1.868 [95% confidence interval (CI): 1.025&#x02013;3.401]. The OR for HARM from cortical infarction was 9.475 (95% CI: 4.754&#x02013;18.883) compared to other anatomic compartments.</p>
</sec>
<sec id="ST4">
<title>Conclusion</title>
<p>The presence of the HARM was significantly associated with embolic infarctions including LAA and CE. Conversely, SVO was exclusively associated with the absence of the HARM. Second, MCA and cortical infarction showed a more pronounced HARM compared to infarctions at other vascular territories and anatomic compartments. According to the results in the current study, we speculate that the presence of HARM on post-contrast FLAIR images was associated with specific stroke causes especially in embolic causes.</p>
</sec>
</abstract>
<kwd-group>
<kwd>hyperintense acute reperfusion marker</kwd>
<kwd>post-contrast fluid-attenuated inversion recovery</kwd>
<kwd>acute stroke</kwd>
<kwd>Trial of ORG 10172 in Acute Stroke Treatment classification</kwd>
<kwd>magnetic resonance imaging</kwd>
</kwd-group>
<contract-num rid="cn01">NRF-2016R1D1A1B03933173</contract-num>
<contract-num rid="cn02">NRF-2017R1E1A2A02067113</contract-num>
<contract-sponsor id="cn01">Ministry of Education<named-content content-type="fundref-id">10.13039/501100002701</named-content></contract-sponsor>
<contract-sponsor id="cn02">National Research Foundation of Korea<named-content content-type="fundref-id">10.13039/501100003725</named-content></contract-sponsor>
<counts>
<fig-count count="5"/>
<table-count count="6"/>
<equation-count count="0"/>
<ref-count count="52"/>
<page-count count="14"/>
<word-count count="9371"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="introduction">
<title>Introduction</title>
<p>Stroke is one of the main causes of death and disability in the world. In the USA, stroke has been one of the leading causes of death since 1924 (<xref ref-type="bibr" rid="B1">1</xref>). The global population comprised a significant number of elderly individuals, causing an increased incidence of age-related diseases such as stroke. Therefore, an accurate definition of the mechanism of stroke is crucial, as this will guide the selection of the most effective care and therapy (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). There are many factors contributing to the overall outcome and prognosis in stroke patients. In addition to other predictors of stroke prognosis, such as neurological severity, age, other comorbidities, and epidemiological factors, the etiological subtype in ischemic stroke is an important factor for predicting the prognosis. For example, patients with lacunar infarcts have a better prognosis up to 1&#x02009;year after onset than other stroke subtypes due to a different pathophysiological mechanism, although the long-term prognosis after lacunar stroke may not greatly differ from that after non-lacunar stroke. In contrast, patients with stroke of cardioembolic (CE) or large artery atherosclerosis (LAA) etiology tend to have worse prognoses for recovery than those with other ischemic stroke subtypes (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). In this context, it is important to appropriately diagnose the patient&#x02019;s etiological subtype of ischemic stroke not only for assisting treatment decisions by physicians but also for designing strategies for secondary stroke prevention (<xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>There are several etiologic classification systems for ischemic stroke, such as the Harvard Stroke Registry (<xref ref-type="bibr" rid="B7">7</xref>), Stroke Data Bank (<xref ref-type="bibr" rid="B8">8</xref>), Trial of ORG 10172 in Acute Stroke Treatment (TOAST) system (<xref ref-type="bibr" rid="B9">9</xref>), Baltimore-Washington system (<xref ref-type="bibr" rid="B10">10</xref>), Causative Classification of Stroke System (CCS) (<xref ref-type="bibr" rid="B11">11</xref>), and atherothrombosis, small vessel disease, cardiac causes, and other uncommon causes (<xref ref-type="bibr" rid="B12">12</xref>). These are further subcategorized into the following two types according to the major approaches for the etiologic classification of stroke: phenotype and causative types. The phenotypic subcategory is determined based on an organization of abnormal test findings that may fit into major etiologic groups. Using this classification, patients could be categorized into more than one etiologic subtype. In contrast, the causative subcategory is assigned according to the most suspicious presumed mechanism of stroke. TOAST and CCS are the most commonly available examples of causative systems. However, with recent advances in diagnostic technology, multiple coexisting potential causes of ischemic stroke are frequently identified, which makes the selection of a causative subgroup a subjective process in clinical practice.</p>
<p>The TOAST classification system is primarily based on clinical features and also incorporates diagnostic information from various modalities including computed tomography, magnetic resonance imaging (MRI), transthoracic echocardiography, extracranial carotid ultrasonography, and cerebral angiography. This classification includes five subtypes of cerebral infarction: (1) LAA, (2) small vessel occlusion (SVO), (3) cardioembolism (CE), (4) strokes of other determined etiology (SOD), and (5) strokes of undetermined etiology (SUD) (Table <xref ref-type="table" rid="T1">1</xref>). The SUDs are further sub-classified into &#x0201C;two or more causes,&#x0201D; &#x0201C;negative evaluation,&#x0201D; and &#x0201C;incomplete evaluation&#x0201D; (<xref ref-type="bibr" rid="B9">9</xref>). Although the TOAST system has been widely used in stroke-related research and in therapeutic studies, it has a few weaknesses. First, the reliability of TOAST classification is only fair to moderate with kappa values ranging from 0.42 to 0.54 (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B13">13</xref>&#x02013;<xref ref-type="bibr" rid="B16">16</xref>). Second, a result of &#x0201C;undetermined etiology&#x0201D; is often reached, partially because patients with more than two causes of stroke are classified as &#x0201C;undetermined etiology,&#x0201D; even though the individual potential causes of stroke are identifiable (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B17">17</xref>). Third, only strokes with more than 50% stenosis of the corresponding artery are classified as LAD (<xref ref-type="bibr" rid="B18">18</xref>). This means that cases with less than 50% stenosis are ignored, despite a potential to generate distal embolization. Fourth, embolic infarctions with vulnerable plaque with less than 50% stenosis are classified as SUD and aortic atherosclerosis is not described in the TOAST system even though CCS is classified as CE. Furthermore, advanced imaging techniques such as high-resolution vessel wall imaging and hemodynamic 4D-flow imaging, which can detect minimal changes in intracranial abnormalities as well as the underlying pathologic changes, can cause more confusion for classifying TOAST subtypes. Complementary classification systems are needed to resolve these problems.</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Characteristics of TOAST stroke subtypes.</p></caption>
<table frame="hsides" rules="groups">
<tbody>
<tr>
<td align="left" valign="top">Large artery atherosclerosis
<list list-type="bullet">
<list-item><p>Duplex scanning or angiography must show greater than 50% stenosis of an extracranial artery relevant to lesion</p></list-item>
<list-item><p>Cortical, cerebellar, brainstem, or subcortical hemispheric infarctions greater than 1.5&#x02009;cm diameter must be present</p></list-item>
<list-item><p>Clinical finding of cerebral cortical impairment, brainstem, or cerebellar dysfunction must be present</p></list-item>
<list-item><p>No apparent source or suspicious cardioembolism can be present</p></list-item>
</list>
</td>
</tr>
<tr>
<td align="left" valign="top">Small vessel occlusion
<list list-type="bullet">
<list-item><p>Patients must have a traditional lacunar syndrome of pure motor stroke, dysarthria or clumsy hand syndrome, or ataxic hemiparesis with no evidence of worsened cerebral cortical function</p></list-item>
<list-item><p>A normal computed tomographic or magnetic resonance imaging scan or a relevant subcortical or brainstem lesion less than 1.5&#x02009;cm in diameter must be present</p></list-item>
<list-item><p>Patients must not have source of cardioembolism or stenosis of relevant extracranial artery of greater than 50%</p></list-item>
</list>
</td>
</tr>
<tr>
<td align="left" valign="top">Cardioembolism
<list list-type="bullet">
<list-item><p>Patient must have radiologic and clinical finding similar to those seen in large artery atherosclerosis: infarctions in multiple vascular distributions are even more suggestive</p></list-item>
<list-item><p>No relevant extracranial artery may have stenosis or greater than 50%</p></list-item>
<list-item><p>A high- or medium-risk cardioembolic source must be identified</p></list-item>
</list>
</td>
</tr>
<tr>
<td align="left" valign="top">Other determined causes
<list list-type="bullet">
<list-item><p>No source of cardioembolism or stenosis of a relevant extracranial artery greater than 50% can be present</p></list-item>
<list-item><p>Other plausible sources must be identified</p></list-item>
<list-item><p>Unknown causes</p></list-item>
<list-item><p>Source cannot be determined, two causes are present, or evaluation is incomplete</p></list-item>
</list>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot><p><italic>TOAST, Trial of ORG 10172 in Acute Stroke Treatment</italic>.</p>
<p><italic>TOAST was the most commonly available examples of causative systems. However, with recent advances in diagnostic technology, multiple coexisting potential causes of ischemic stroke are frequently identified, which makes the selection of a causative subgroup a subjective process in clinical practice</italic>.</p></table-wrap-foot></table-wrap>
<p>In this study, we focused on the hyperintense acute reperfusion marker (HARM) in post-contrast fluid-attenuated inversion recovery (FLAIR) images in patients with acute ischemic stroke to resolve the problems of TOAST classification. The HARM is defined as a delayed enhancement of the subarachnoid or subpial space on post-contrast FLAIR images in patients with acute stroke and is believed to be associated with permeability changes in the blood&#x02013;brain barrier (BBB) (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>). It has been reported that BBB breakdown, as indicated by HARM, was more common in patients who underwent reperfusion and was exacerbated by thrombolytic therapy (<xref ref-type="bibr" rid="B20">20</xref>). Recently, Ostwaldt et al. (<xref ref-type="bibr" rid="B21">21</xref>) demonstrated an association of HARM with early contrast material enhancement of the infarcted area in acute stroke and Lee et al. (<xref ref-type="bibr" rid="B22">22</xref>) reported that early HARM sign in acute stroke patients and most of HARM sign in that study was founded in the LAA and CE infarctions. They speculated that HARM may occur frequently in association with small embolic infarctions or reperfusion. We also recently observed relative high incidence of HARM in the specific cause of ischemic stroke. This study is based on <italic>a priori</italic> hypothesis: Embolic subtypes of acute stroke (e.g., LAA and CE) show more HARM compared with other subtypes of acute ischemic stroke based on conventional TOAST classifications. Therefore, the aims of this study were (1) to demonstrate the relationship between HARM and causative stroke etiology based on conventional TOAST classification and (2) to evaluate the relationship between HARM and stroke locations with respect to vascular territories and anatomic compartments. Based on the regions involved, HARM assessments were dichotomized into &#x0201C;regional pattern&#x0201D; and &#x0201C;randomized pattern.&#x0201D; The regional pattern described a HARM localization correlating with the same vascular territory as the acute infarction whereas the randomized pattern was assigned when a generalized contrast enhancement was detected in the ipsilateral or contralateral cerebral cortex regardless of acute infarction. Ultimately, we are going to evaluate the role of HARM for classifying stroke etiology based on TOAST classification. Understanding the clinical significance of HARM in acute stroke and incorporating these findings into the stroke subtype classification scheme may be a rational approach for acute stroke treatment and prevention.</p>
</sec>
<sec id="S2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="S2-1">
<title>Subjects and Demographic Data</title>
<sec id="S2-1-1">
<title>Patient Selection</title>
<p>We enrolled patients admitted to our hospital between May 2015 and March 2016 who met all the following eligibility criteria: diagnosed with acute ischemic stroke; underwent conventional brain MRI including post-contrast FLAIR within 7&#x02009;days of symptom onset; and showed relevant lesions upon DWI for this retrospective study. During the study period, 347 patients with acute ischemic stroke were admitted to our hospital. After excluding 79 patients due to an absence of post-contrast FLAIR and 4 patients due to a lack of information on the TOAST classification, a total of 264 patients were enrolled in this study. The study population comprised 155 male and 109 female patients with a mean age of 68.63&#x02009;&#x000B1;&#x02009;11.14&#x02009;years (range 29&#x02013;92&#x02009;years).</p>
<p>This study was approved by the institutional review board of our institute.</p>
</sec>
<sec id="S2-1-2">
<title>Clinical Assessment</title>
<p>Patient evaluation was performed by an experienced stroke neurologist. Symptom severity and neurologic recovery were assessed using the National Institute of Health Stroke Scale (NIHSS) scores at admission and discharge. We also analyzed the changes in score from admission to discharge for assessing neurologic recovery. In addition, we used modified Rankin scale (mRS) scores at discharge as a measure of clinical outcomes.</p>
<p>Other data such as patient demographics, medical history, and risk factors were obtained directly from the web-based stroke registry, known as the prospective stroke registry of the fifth section of the Clinical Research Center for Stroke. Clinical symptoms were classified as lacunar syndrome (including pure motor hemiparesis, pure sensory stroke, sensory-motor stroke, ataxic hemiparesis, dysarthria syndrome, and dysarthria-clumsy hand syndrome) or the non-lacunar syndrome, which was considered when cortical signs (aphasia, neglect, gaze deviation, or altered consciousness) were present. The stroke onset time was defined as the last known time at which the patient was free of symptoms. The potential stroke mechanisms were determined using the conventional TOAST classification and include presenting the atrial fibrillation as a contributing factor for cardioembolic evaluation.</p>
</sec>
</sec>
<sec id="S2-2">
<title>MRI Acquisition</title>
<p>Magnetic resonance imaging was performed on a 3&#x02009;T MRI system (Achieva; Philips Medical Systems, Best, The Netherlands) equipped with an eight-channel head coil. The protocol for conventional brain MR evaluation included DWI, T2-weighted imaging, T1WI (sagittal plane), FLAIR, gradient-echo imaging, post-contrast T1WI (axial and sagittal planes), post-contrast FLAIR, and vascular imaging including three-dimensional time-of-flight (3D TOF) intracranial MRA and post-contrast MRA encompassing the extracranial internal carotid artery (ICA) and vertebral artery.</p>
<sec id="S2-2-1">
<title>Post-Contrast FLAIR Imaging</title>
<p>Patients received gadolinium at a dose of 0.2&#x02009;mmol/kg and post-contrast FLAIR images were taken 5&#x02009;min later. The post-contrast FLAIR images were obtained in the axial plane using a turbo spin-echo sequence with a section thickness of 5&#x02009;mm, an intersection gap of 0.5&#x02009;mm, a field of view (FOV) of 182&#x02009;mm&#x02009;&#x000D7;&#x02009;230&#x02009;mm, a TR/TE of 11,000/125&#x02009;ms, and a matrix number of 352&#x02009;&#x000D7;&#x02009;176.</p>
</sec>
<sec id="S2-2-2">
<title>DWI Imaging</title>
<p>DWI was performed in the axial plane with a section thickness of 5&#x02009;mm, an intersection gap of 0.5&#x02009;mm, an FOV of 230&#x02009;mm&#x02009;&#x000D7;&#x02009;230&#x02009;mm, a TR/TE of 3,000/50&#x02009;ms, and a matrix number of 128&#x02009;&#x000D7;&#x02009;128. The <italic>b</italic> values corresponding to the diffusion-sensitizing gradient were 0 and 1,000&#x02009;s/mm<sup>2</sup>. Apparent diffusion coefficient maps were derived automatically on a pixel-by-pixel basis from the DWI.</p>
</sec>
<sec id="S2-2-3">
<title>Vascular Imaging</title>
<p>A 3D TOF intracranial MRA was performed with a section thickness of 1.6&#x02009;mm, an intersection gap of 0.8&#x02009;mm, an FOV of 200&#x02009;mm&#x02009;&#x000D7;&#x02009;200&#x02009;mm, a TR/TE of 25/3.45&#x02009;ms, and a matrix number of 500&#x02009;&#x000D7;&#x02009;286. A 3D post-contrast extracranial MRA from the aortic arch was performed with a section thickness of 1&#x02009;mm, an intersection gap of 0.5&#x02009;mm, an FOV of 330&#x02009;mm&#x02009;&#x000D7;&#x02009;330&#x02009;mm, a TR/TE of 5.3/2.1&#x02009;ms, and a matrix number of 708&#x02009;&#x000D7;&#x02009;708.</p>
</sec>
</sec>
<sec id="S2-3">
<title>Image Analysis</title>
<p>Two experienced neuro-radiologists blinded to the patient&#x02019;s clinical information performed the visual analysis of MR images.</p>
<sec id="S2-3-1">
<title>Acute Infarction on DWI</title>
<p>The location of acute infarct was classified into subgroups according to the involved areas with respect to the vascular territory and anatomic location. The subcategories of acute infarction according to vascular territories were as follows: ICA, anterior cerebral artery, middle cerebral artery (MCA), posterior cerebral artery (PCA), basilar artery (BA), superior cerebellar artery, anterior inferior cerebellar artery, posterior inferior cerebellar artery, border zone, and multiple. The subcategories of acute infarction according to anatomic location were as follows: cortex, corona radiata, basal ganglia/internal capsule, thalamus, brainstem, and cerebellum.</p>
</sec>
<sec id="S2-3-2">
<title>HARM on Post-Contrast FLAIR Imaging</title>
<p>Hyperintense acute reperfusion marker on post-contrast FLAIR images was considered positive when cortical and sulcal contrast retention was observed. We evaluated the overall HARM incidence in patients with acute ischemic stroke in this study. We further evaluated the relative HARM incidence within each causative stroke etiology subgroup based on the conventional TOAST classification. We also accounted for the HARM pattern while evaluating the relationship between HARM and stroke etiology based on the conventional TOAST classification. The pattern of HARM was categorized by vascular territory. Based on the regions involved, HARM assessments were dichotomized into &#x0201C;regional pattern&#x0201D; and &#x0201C;randomized pattern.&#x0201D; The regional pattern described a HARM localization correlating with the same vascular territory as the acute infarction. In contrast, the randomized pattern was assigned when a generalized contrast enhancement was detected in the ipsilateral or contralateral cerebral cortex regardless of acute infarction.</p>
</sec>
</sec>
<sec id="S2-4">
<title>Statistical Analysis</title>
<p>Values are presented as mean&#x02009;&#x000B1;&#x02009;SD or median (with interquartile ranges) for continuous variables and as the number of subjects (%) for categorical variables. The differences in the clinical characteristics and stroke risk factors among stroke subtypes were evaluated using the Kruskal&#x02013;Wallis test for continuous variables and the Chi-square test (or Fisher&#x02019;s exact test) for categorical variables. The Mann&#x02013;Whitney <italic>U</italic>-test was used for evaluating differences in the aforementioned factors between HARM-positive and -negative groups. The differences in relative HARM incidence among stroke subtypes were evaluated using the Chi-square test (or Fisher&#x02019;s exact test). In addition, for multiple comparisons, <italic>p</italic>-values were adjusted according to Bonferroni&#x02019;s method. We also used the Chi-square test (or Fisher&#x02019;s exact test) for evaluating the differences in HARM patterns among stroke subtypes. We accounted for the stroke location while evaluating the relationship between HARM and stroke etiology based on the conventional TOAST classification. The relationship between relative HARM incidence and stroke location based on vascular territory and anatomical compartments was expressed as an odds ratio (OR) with corresponding 95% confidence interval (CI) by logistic regression analysis. <italic>p</italic>-Values &#x0003C;0.05 were deemed statistically significant. All statistical analyses were performed using SPSS version 23.0 (IBM corp., Armonk, NY, USA).</p>
</sec>
</sec>
<sec id="S3">
<title>Results</title>
<sec id="S3-1">
<title>Patient Demographics and Stroke Characteristics</title>
<p>The sex, age, stroke risk factors, and stroke characteristics of patients are presented in Table <xref ref-type="table" rid="T2">2</xref>.</p>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>Demographics and stroke characteristics of patients according to the presence of HARM.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left" rowspan="2">Variable</th>
<th valign="top" align="center" rowspan="2"/>
<th valign="top" align="center" rowspan="2">Total (<italic>n</italic>&#x02009;&#x0003D;&#x02009;264)</th>
<th valign="top" align="center" colspan="2">HARM (&#x0002B;) (<italic>n</italic>&#x02009;&#x0003D;&#x02009;67)<hr/></th>
<th valign="top" align="center" rowspan="2">HARM (&#x02212;) (<italic>n</italic>&#x02009;&#x0003D;&#x02009;197)</th>
<th valign="top" align="center" rowspan="2"><italic>p</italic>-Value</th>
</tr>
<tr>
<th valign="top" align="center">Regional (<italic>n</italic>&#x02009;&#x0003D;&#x02009;55)</th>
<th valign="top" align="center">Randomized (<italic>n</italic>&#x02009;&#x0003D;&#x02009;12)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Sex (<italic>n</italic>)</td>
<td align="left" valign="top">Male</td>
<td align="center" valign="top">155 (58.71%)</td>
<td align="center" valign="top">37 (66.07%)</td>
<td align="center" valign="top">6 (50%)</td>
<td align="center" valign="top">114 (57%)</td>
<td align="center" valign="top">0.367</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">Female</td>
<td align="center" valign="top">109 (41.29%)</td>
<td align="center" valign="top">19 (33.93%)</td>
<td align="center" valign="top">6 (50%)</td>
<td align="center" valign="top">86 (43%)</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Age</td>
<td align="left" valign="top">Mean&#x02009;&#x000B1;&#x02009;SD</td>
<td align="center" valign="top">68.63&#x02009;&#x000B1;&#x02009;11.14</td>
<td align="center" valign="top">68.88&#x02009;&#x000B1;&#x02009;10.85</td>
<td align="center" valign="top">71.42&#x02009;&#x000B1;&#x02009;14.82</td>
<td align="center" valign="top">68.44&#x02009;&#x000B1;&#x02009;10.97</td>
<td align="center" valign="top">0.301</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">Median</td>
<td align="center" valign="top">70.50</td>
<td align="center" valign="top">71.00</td>
<td align="center" valign="top">74.00</td>
<td align="center" valign="top">70.00</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="7"><bold>Risk factors (<italic>n</italic>)</bold></td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;HTN (<italic>n</italic>)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">186</td>
<td align="center" valign="top">40</td>
<td align="center" valign="top">8</td>
<td align="center" valign="top">140</td>
<td align="center" valign="top">0.971</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;DM (<italic>n</italic>)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">95</td>
<td align="center" valign="top">21</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">71</td>
<td align="center" valign="top">0.872</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Dyslipidemia (<italic>n</italic>)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">176</td>
<td align="center" valign="top">39</td>
<td align="center" valign="top">7</td>
<td align="center" valign="top">130</td>
<td align="center" valign="top">0.727</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Smoking (<italic>n</italic>)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">121</td>
<td align="center" valign="top">29</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">90</td>
<td align="center" valign="top">0.793</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Stroke Hx (<italic>n</italic>)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">39</td>
<td align="center" valign="top">7</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">30</td>
<td align="center" valign="top">0.722</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Large artery occlusion (<italic>n</italic>)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">75</td>
<td align="center" valign="top">26</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">45</td>
<td align="center" valign="top">0.0006</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Reperfusion therapy (<italic>n</italic>)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">26</td>
<td align="center" valign="top">7</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">18</td>
<td align="center" valign="top">0.506</td>
</tr>
<tr>
<td align="left" valign="top">Time between symptom onset to MRI acquisition</td>
<td align="left" valign="top">Mean&#x02009;&#x000B1;&#x02009;SD</td>
<td align="center" valign="top">18&#x02009;h and 07&#x02009;min</td>
<td align="center" valign="top">20&#x02009;h and 33&#x02009;min</td>
<td align="center" valign="top">21&#x02009;h and 24&#x02009;min</td>
<td align="center" valign="top">17&#x02009;h and 14&#x02009;min</td>
<td align="center" valign="top">0.118</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">Median</td>
<td align="center" valign="top">12&#x02009;h and 57&#x02009;min</td>
<td align="center" valign="top">13&#x02009;h and 5&#x02009;min</td>
<td align="center" valign="top">15&#x02009;h and 54&#x02009;min</td>
<td align="center" valign="top">12&#x02009;h and 50&#x02009;min</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">NIHSS at admission</td>
<td align="left" valign="top">Mean&#x02009;&#x000B1;&#x02009;SD</td>
<td align="center" valign="top">4.24&#x02009;&#x000B1;&#x02009;3.98</td>
<td align="center" valign="top">4.15&#x02009;&#x000B1;&#x02009;3.14</td>
<td align="center" valign="top">4.83&#x02009;&#x000B1;&#x02009;3.87</td>
<td align="center" valign="top">4.23&#x02009;&#x000B1;&#x02009;4.18</td>
<td align="center" valign="top">0.480</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">Median</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">4.5</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">NIHSS at discharge</td>
<td align="left" valign="top">Mean&#x02009;&#x000B1;&#x02009;SD</td>
<td align="center" valign="top">3.30&#x02009;&#x000B1;&#x02009;3.83</td>
<td align="center" valign="top">3.60&#x02009;&#x000B1;&#x02009;4.10</td>
<td align="center" valign="top">4.75&#x02009;&#x000B1;&#x02009;7.29</td>
<td align="center" valign="top">2.13&#x02009;&#x000B1;&#x02009;3.40</td>
<td align="center" valign="top">0.006</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">Median</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">NIHSS changes (discharge&#x02009;&#x02212;&#x02009;admission)</td>
<td align="left" valign="top">Mean&#x02009;&#x000B1;&#x02009;SD</td>
<td align="center" valign="top">&#x02212;0.94&#x02009;&#x000B1;&#x02009;3.80</td>
<td align="center" valign="top">&#x02212;0.55&#x02009;&#x000B1;&#x02009;3.83</td>
<td align="center" valign="top">&#x02212;0.08&#x02009;&#x000B1;&#x02009;8.76</td>
<td align="center" valign="top">&#x02212;1.10&#x02009;&#x000B1;&#x02009;3.23</td>
<td align="center" valign="top">0.053</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">Median</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">mRS at discharge</td>
<td align="left" valign="top">Mean&#x02009;&#x000B1;&#x02009;SD</td>
<td align="center" valign="top">2.05&#x02009;&#x000B1;&#x02009;1.31</td>
<td align="center" valign="top">2.13&#x02009;&#x000B1;&#x02009;1.32</td>
<td align="center" valign="top">2.25&#x02009;&#x000B1;&#x02009;1.59</td>
<td align="center" valign="top">2.01&#x02009;&#x000B1;&#x02009;1.30</td>
<td align="center" valign="top">0.418</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">Median</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top"/>
</tr>
</tbody>
</table>
<table-wrap-foot><p><italic>HARM, hyperintense acute reperfusion marker; HTN, hypertension; DM, diabetes; Hx, history; NIHSS, National Institute of Health Stroke Scale; MRI, magnetic resonance imaging; mRS, Modified Rankin scale</italic>.</p>
<p><italic>Table shows the univariate associations between the demographics, stroke characteristics and the presence of HARM. There was statistically significant difference in NIHSS at discharge between HARM-positive and -negative groups. Except NIHSS at discharge, other clinical variables were similar and there were no statistically significant differences between the HARM-positive and -negative groups</italic>.</p></table-wrap-foot></table-wrap>
<p>Large artery occlusion was observed in 75 patients in total included patients and 30 patients in HARM-positive groups and 45 patients in HARM-negative group.</p>
<p>Twenty-four patients received intravenous (IV) tissue plasminogen activator (tPA), and two patients with cardioembolic stroke received IV tPA plus intraarterial (IA) thrombolysis. The remaining 238 patients were conservatively treated before MRI.</p>
<p>The mean time interval between the onset of stroke symptoms and MRI acquisition in total included patients was 18&#x02009;h and 7&#x02009;min (median 12&#x02009;h 57&#x02009;min, range 2&#x02013;127&#x02009;h). However, most of the patient included in current study took MRI within 48&#x02009;h since symptom onset (240/264, 90%).</p>
<p>The median NIHSS score in total included patients at admission was 4 (range 0&#x02013;28) and that at discharge was 2 (range 0&#x02013;28). In addition, the median mRS score at discharge was 2 (range 0&#x02013;5). However, the clinical significance of mRS scores at discharge was limited because the time interval between admission and discharge varied between 0 and 144&#x02009;days (median 8&#x02009;days).</p>
<p>In this study population, SVO was the most common cause of acute ischemic stroke (33.3%), followed by LAA (28.4%), SUD (25.0%), CE (11.7%), and SOD (0.02%), based on the conventional TOAST classification. Among the SUD cases (<italic>n</italic>&#x02009;&#x0003D;&#x02009;66), negative causes were the most common etiology (<italic>n</italic>&#x02009;&#x0003D;&#x02009;40), followed by two or more causes (<italic>n</italic>&#x02009;&#x0003D;&#x02009;15), and incomplete work-ups (<italic>n</italic>&#x02009;&#x0003D;&#x02009;11).</p>
<p>With respect to stroke location according to the involved vascular territory, MCA was the most frequently involved vascular territory of the stroke location (<italic>n</italic>&#x02009;&#x0003D;&#x02009;164), followed by PCA (<italic>n</italic>&#x02009;&#x0003D;&#x02009;45) and BA (<italic>n</italic>&#x02009;&#x0003D;&#x02009;37). With respect to stroke location based on anatomic compartments, DWI demonstrated acute ischemic infarction in the cortex in 122 patients, in the corona radiata in 86 patients, in the basal ganglia/internal capsule in 89 patients, in the thalamus in 30 patients, in the brainstem in 32 patients, and in the cerebellum in 19 patients.</p>
</sec>
<sec id="S3-2">
<title>Relationship between HARM and Causative Stroke Etiology Based on Conventional TOAST Classification</title>
<p>Among the 264 patients with acute ischemic stroke, 67 (25.38%) patients were HARM-positive while and 197 (74.62%) patients were HARM-negative (Table <xref ref-type="table" rid="T3">3</xref>A). We evaluated the relative HARM incidence between subgroups of stroke etiology based on the conventional TOAST classification: there was a significant difference in relative HARM incidence among the stroke subgroups (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001) (Table <xref ref-type="table" rid="T3">3</xref>A). Table <xref ref-type="table" rid="T3">3</xref>B shows the relatively higher incidence of HARM in the LAA group (40%) than in the other subgroups (19.57%) (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.001). In addition, the relative HARM incidence in LAA plus CE (36.79%) subgroup was significantly higher compared to that in the other subgroups (17.72%) (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001) (Table <xref ref-type="table" rid="T3">3</xref>C; Figures <xref ref-type="fig" rid="F1">1</xref> and <xref ref-type="fig" rid="F2">2</xref>). Table <xref ref-type="table" rid="T3">3</xref>D shows a significantly lower incidence of HARM in the SVO subgroup (6.81%) than in the other subgroups (34.65%) (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001). The relative HARM incidence was significantly different between the LAA and SVO (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.001), SVO and CE (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.016), and SVO and SUD subgroups (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.001) (Table <xref ref-type="table" rid="T4">4</xref>; Figure <xref ref-type="fig" rid="F3">3</xref>).</p>
<table-wrap position="float" id="T3">
<label>Table 3</label>
<caption><p>Relative HARM incidence of patients according to stroke subtypes.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left"/>
<th valign="top" align="center" colspan="8">TOAST<hr/></th>
<th valign="top" align="center" colspan="3"><italic>p</italic>-Value<hr/></th>
</tr>
<tr>
<th valign="top" align="left"/>
<th valign="top" align="center">Total (<italic>n</italic>&#x02009;&#x0003D;&#x02009;264)</th>
<th valign="top" align="center">1. LAA (<italic>n</italic>&#x02009;&#x0003D;&#x02009;75)</th>
<th valign="top" align="center">2. SVO (<italic>n</italic>&#x02009;&#x0003D;&#x02009;88)</th>
<th valign="top" align="center">3. CE (<italic>n</italic>&#x02009;&#x0003D;&#x02009;31)</th>
<th valign="top" align="center">4. SOD (<italic>n</italic>&#x02009;&#x0003D;&#x02009;4)</th>
<th valign="top" align="center" colspan="3">5. SUD (<italic>n</italic>&#x02009;&#x0003D;&#x02009;66)</th>
<th valign="top" align="center">Among subtypes</th>
<th valign="top" align="center">LAA vs. other subtypes</th>
<th valign="top" align="center">SVO vs. other subtypes</th>
</tr>
<tr>
<th valign="top" align="center" colspan="6"/>
<th valign="top" align="center" colspan="3"><hr/></th>
<th valign="top" align="center" colspan="3"><hr/></th>
</tr>
<tr>
<th valign="top" align="left"/>
<th valign="top" align="center"/>
<th valign="top" align="center"/>
<th valign="top" align="center"/>
<th valign="top" align="center"/>
<th valign="top" align="center"/>
<th valign="top" align="center">SUDm (<italic>n</italic>&#x02009;&#x0003D;&#x02009;15)</th>
<th valign="top" align="center">SUDn (<italic>n</italic>&#x02009;&#x0003D;&#x02009;40)</th>
<th valign="top" align="center">SUDi (<italic>n</italic>&#x02009;&#x0003D;&#x02009;11)</th>
<th valign="top" align="center"/>
<th valign="top" align="center"/>
<th valign="top" align="center"/>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" colspan="12" style="background-color:#949599;"><bold>(A) OVERALL TOAST ETIOLOGIC SUBGROUPS</bold></td>
</tr>
<tr>
<td align="left" valign="top">HARM (&#x0002B;)</td>
<td align="center" valign="top">67</td>
<td align="center" valign="top">30</td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">13</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">&#x0003C;0.0001</td>
<td align="center" valign="top">0.001</td>
<td align="center" valign="top">&#x0003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">HARM (&#x02212;)</td>
<td align="center" valign="top">197</td>
<td align="center" valign="top">45</td>
<td align="center" valign="top">82</td>
<td align="center" valign="top">22</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">27</td>
<td align="center" valign="top">7</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="12" style="background-color:#949599;"><bold>(B) LAA VS. OTHER SUBGROUP</bold></td>
</tr>
<tr>
<td align="center" valign="top"/>
<td align="center" valign="top" colspan="3"><bold>TOAST</bold><hr/></td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="center" valign="top"/>
<td align="center" valign="top"><bold>LAA (<italic>n</italic>&#x02009;&#x0003D;&#x02009;75)</bold></td>
<td align="center" valign="top"><bold>Others (<italic>n</italic>&#x02009;&#x0003D;&#x02009;189)</bold></td>
<td align="center" valign="top"><bold><italic>p</italic>-Value</bold></td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="4"><hr/></td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">HARM (&#x0002B;) (<italic>n</italic>&#x02009;&#x0003D;&#x02009;67)</td>
<td align="center" valign="top">30 (40%)</td>
<td align="center" valign="top">37 (19.57%)</td>
<td align="center" valign="top">0.001</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">HARM (&#x02212;) (<italic>n</italic>&#x02009;&#x0003D;&#x02009;197)</td>
<td align="center" valign="top">45 (60%)</td>
<td align="center" valign="top">152 (82.42%)</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="justify" valign="top" colspan="12" style="background-color:#949599;"><bold>(C) LAA PLUS CE VS. OTHER GROUP</bold></td>
</tr>
<tr>
<td align="center" valign="top"/>
<td align="center" valign="top" colspan="3"><bold>TOAST</bold><hr/></td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="center" valign="top"/>
<td align="center" valign="top"><bold>CE&#x02009;&#x0002B;&#x02009;LAA (<italic>n</italic>&#x02009;&#x0003D;&#x02009;106)</bold></td>
<td align="center" valign="top"><bold>Others (<italic>n</italic>&#x02009;&#x0003D;&#x02009;158)</bold></td>
<td align="center" valign="top"><bold><italic>p</italic>-Value</bold></td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="4"><hr/></td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">HARM (&#x0002B;) (<italic>n</italic>&#x02009;&#x0003D;&#x02009;67)</td>
<td align="center" valign="top">39 (36.79%)</td>
<td align="center" valign="top">28 (17.72%)</td>
<td align="center" valign="top">&#x0003C;0.001</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">HARM (&#x02212;) (<italic>n</italic>&#x02009;&#x0003D;&#x02009;197)</td>
<td align="center" valign="top">67 (63.21%)</td>
<td align="center" valign="top">130 (82.28%)</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="12" style="background-color:#949599;"><bold>(D) SVO VS. OTHER SUBGROUPS</bold></td>
</tr>
<tr>
<td align="center" valign="top"/>
<td align="center" valign="top" colspan="3"><bold>TOAST</bold><hr/></td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="center" valign="top"/>
<td align="center" valign="top"><bold>SVO (<italic>n</italic>&#x02009;&#x0003D;&#x02009;88)</bold></td>
<td align="center" valign="top"><bold>Others (<italic>n</italic>&#x02009;&#x0003D;&#x02009;176)</bold></td>
<td align="center" valign="top"><bold><italic>p</italic>-Value</bold></td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="4"><hr/></td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">HARM (&#x0002B;) (<italic>n</italic>&#x02009;&#x0003D;&#x02009;67)</td>
<td align="center" valign="top">6 (6.81%)</td>
<td align="center" valign="top">61 (34.65%)</td>
<td align="center" valign="top">&#x0003C;0.001</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">HARM (&#x02212;) (<italic>n</italic>&#x02009;&#x0003D;&#x02009;197)</td>
<td align="center" valign="top">82 (93.18%)</td>
<td align="center" valign="top">115 (65.34%)</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
</tbody>
</table>
<table-wrap-foot><p><italic>HARM, hyperintense acute reperfusion marker; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; LAA, large artery atherosclerosis; SVO, small vessel occlusion; CE, cardioembolism; SOD, strokes of other determined etiology; SUD, strokes of undetermined etiology; SUDm, two or more causes; SUDn, negative evaluation; SUDi, incomplete evaluation</italic>.</p>
<p><italic>Among the 264 patients with acute ischemic stroke, 67 (25.38%) patients were HARM positive while, 197 (74.62%) patients were HARM negative (A). (B) The relatively higher incidence of HARM in the LAA group (40%) than in the other subgroups (19.57%) (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.001). (C) The relative HARM incidence in LAA plus CE (36.79%) subgroup was significantly higher compared with that in the other subgroups (17.72%) (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001). (D) A significantly lower incidence of HARM in the SVO subgroup (6.81%) than in the other subgroups (34.65%) (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001)</italic>.</p></table-wrap-foot></table-wrap>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>A 72-year-old male with a complaint of acute onset left arm weakness. Stroke due to large artery to artery atherosclerosis. <bold>(A)</bold> DWI shows acute border zone infarctions on the right cerebral hemisphere. <bold>(B)</bold> Three-dimensional time-of-flight MRA of extracranial arteries shows moderate-to-severe stenosis with plaque at right proximal internal carotid artery and ECA (arrows). Compared with non-contrast fluid-attenuated inversion recovery (FLAIR) <bold>(C)</bold>, the post-contrast FLAIR <bold>(D)</bold> image shows diffuse sulcal enhancement (hyperintense acute reperfusion marker sign) along the right cerebral sulci (arrows).</p></caption>
<graphic xlink:href="fneur-08-00630-g001.tif"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>A 53-year-old female with a complaint of acute onset aphasia. Stroke due to cardioembolic. <bold>(A)</bold> DWI shows large diffusion restricted lesion on the left frontoparietotemporal lobes. <bold>(B)</bold> Post-contrast fluid-attenuated inversion recovery image shows sulcal enhancement along the left frontoparietal sulci (arrows) compatible with hyperintense acute reperfusion marker. <bold>(C)</bold> Gradient-echo imaging image shows blooming artifact at the left proximal MCA (arrowhead) indicating intravascular thrombus. Note, hemorrhagic foci of stroke area at the left temporal lobe. <bold>(D)</bold> Three-dimensional time-of-flight MRA shows occlusion of proximal M1 segment of left MCA (arrowhead). There is no stenoocclusive lesion in the cervical arteries (not shown).</p></caption>
<graphic xlink:href="fneur-08-00630-g002.tif"/>
</fig>
<table-wrap position="float" id="T4">
<label>Table 4</label>
<caption><p>Multiple comparisons of the relative HARM incidence according to stroke subtypes.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left"/>
<th valign="top" align="center">LAA vs. SVO</th>
<th valign="top" align="center">LAA vs. CE</th>
<th valign="top" align="center">LAA vs. SOD</th>
<th valign="top" align="center">LAA vs. SUD</th>
<th valign="top" align="center">SVO vs. CE</th>
<th valign="top" align="center">SVO vs. SOD</th>
<th valign="top" align="center">SVO vs. SUD</th>
<th valign="top" align="center">CE vs. SOD</th>
<th valign="top" align="center">CE vs. SUD</th>
<th valign="top" align="center">SOD vs. SUD</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top"><italic>p</italic>-Value</td>
<td align="center" valign="top">0.011&#x0002A;</td>
<td align="center" valign="top">1.000</td>
<td align="center" valign="top">1.000</td>
<td align="center" valign="top">1.000</td>
<td align="center" valign="top">0.016&#x0002A;&#x0002A;</td>
<td align="center" valign="top">0.366</td>
<td align="center" valign="top">0.001&#x0002A;&#x0002A;&#x0002A;</td>
<td align="center" valign="top">1.000</td>
<td align="center" valign="top">1.000</td>
<td align="center" valign="top">1.000</td>
</tr>
</tbody>
</table>
<table-wrap-foot><p><italic>HARM, hyperintense acute reperfusion marker; LAA, large artery atherosclerosis; SVO, small vessel occlusion; CE, cardioembolism; SOD, strokes of other determined etiology; SUD, strokes of undetermined etiology</italic>.</p>
<p><italic>Table shows the relative HARM incidence was significantly different between the LAA and SVO (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.001), SVO and CE (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.016), and SVO and SUD (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.001) subgroups</italic>.</p></table-wrap-foot></table-wrap>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p>Multiple comparisons of the relative hyperintense acute reperfusion marker (HARM) incidence according to stroke subtypes.</p></caption>
<graphic xlink:href="fneur-08-00630-g003.tif"/>
</fig>
<p>Of the 67 patients in the HARM-positive group, 55 patients showed a regional pattern of HARM with linear enhancement on the same vascular territory as the acute infarction, whereas 12 patients showed a randomized pattern of HARM with linear enhancement on multiple vascular territories in the ipsilateral or contralateral cerebral cortex regardless of acute infarction (Figures <xref ref-type="fig" rid="F4">4</xref> and <xref ref-type="fig" rid="F5">5</xref>). Table <xref ref-type="table" rid="T5">5</xref> shows the relative HARM incidences and HARM patterns between subgroups of stroke etiology. There was a statistically significant difference in HARM patterns among different subtypes (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001). LAA showed a significant association with the regional HARM pattern, compared with the other subgroups (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.002).</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption><p>A 59-year-old male with a complaint of acute onset left side visual field defect in both eyes. Regional pattern of hyperintense acute reperfusion marker. <bold>(A)</bold> DWI shows acute infarction at the right occipital lobe involving the visual cortex. <bold>(B)</bold> Post-contrast fluid-attenuated inversion recovery image shows sulcal enhancement along the right occipital lobe (arrows). Compared with outside CTA <bold>(C)</bold>, three-dimensional time-of-flight MRA <bold>(D)</bold> shows the recanalization state of right distal posterior cerebral artery (dashed arrows).</p></caption>
<graphic xlink:href="fneur-08-00630-g004.tif"/>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption><p>A 82-year-old female with a complaint of acute onset dizziness. Randomized pattern of hyperintense acute reperfusion marker. <bold>(A,B)</bold> Post-contrast fluid-attenuated inversion recovery images show a diffuse, multifocal sulcal enhancement along both cerebral hemispheres (red arrows). <bold>(C)</bold> Three-dimensional time-of-flight MRA of cervical arteries does not show a stenoocclusive lesion. Furthermore, there was no stenoocclusive lesion in the intracranial arteries (not shown). <bold>(D)</bold> Contrast-enhanced T1WI shows multiple nodular or dot-like enhancing lesions (white arrows) on both cerebral hemispheres (not fully shown in this image) indicating acute to subacute stage infarctions.</p></caption>
<graphic xlink:href="fneur-08-00630-g005.tif"/>
</fig>
<table-wrap position="float" id="T5">
<label>Table 5</label>
<caption><p>Relative HARM incidence and HARM patterns of patients according to stroke subtypes.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top"/>
<th align="center" valign="top" colspan="8">TOAST<hr/></th>
<th align="center" valign="top" colspan="3"><italic>p</italic>-Value<hr/></th>
</tr>
<tr>
<th align="left" valign="top"/>
<th align="left" valign="top" rowspan="2">Total (<italic>n</italic>&#x02009;&#x0003D;&#x02009;264)</th>
<th align="center" valign="top" rowspan="2">1. LAA (<italic>n</italic>&#x02009;&#x0003D;&#x02009;75)</th>
<th align="center" valign="top" rowspan="2">2. SVO (<italic>n</italic>&#x02009;&#x0003D;&#x02009;88)</th>
<th align="center" valign="top" rowspan="2">3. CE (<italic>n</italic>&#x02009;&#x0003D;&#x02009;31)</th>
<th align="center" valign="top" rowspan="2">4. SOD (<italic>n</italic>&#x02009;&#x0003D;&#x02009;4)</th>
<th align="center" valign="top" colspan="3">5. SUD (<italic>n</italic>&#x02009;&#x0003D;&#x02009;66)<hr/></th>
<th align="center" valign="top" rowspan="2">Among subtypes</th>
<th align="center" valign="top" rowspan="2">LAA vs. other subtypes</th>
<th align="center" valign="top" rowspan="2">SVO vs. other subtypes</th>
</tr>
<tr>
<th align="left" valign="top"/>
<th align="center" valign="top">SUDm (<italic>n</italic>&#x02009;&#x0003D;&#x02009;15)</th>
<th align="center" valign="top">SUDn (<italic>n</italic>&#x02009;&#x0003D;&#x02009;40)</th>
<th align="center" valign="top">SUDi (<italic>n</italic>&#x02009;&#x0003D;&#x02009;11)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">HARM (&#x0002B;)</td>
<td align="center" valign="top">67</td>
<td align="center" valign="top">30</td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">13</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Regional</td>
<td align="center" valign="top">55</td>
<td align="center" valign="top">26</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">8</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">&#x0003C;0.0001</td>
<td align="center" valign="top">0.002</td>
<td align="center" valign="top">&#x0003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">Randomized</td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">HARM (&#x02212;)</td>
<td align="center" valign="top">197</td>
<td align="center" valign="top">45</td>
<td align="center" valign="top">82</td>
<td align="center" valign="top">22</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">27</td>
<td align="center" valign="top">7</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
</tbody>
</table>
<table-wrap-foot><p><italic>HARM, hyperintense acute reperfusion marker; LAA, large artery atherosclerosis; SVO, small vessel occlusion; CE, cardioembolism; SOD, strokes of other determined etiology; SUD, strokes of undetermined etiology; SUDm, two or more causes; SUDn, negative evaluation; SUDi, incomplete evaluation; TOAST, Trial of ORG 10172 in Acute Stroke Treatment</italic>.</p>
<p><italic>Table shows the relative HARM incidences and HARM patterns between subgroups of stroke etiology. There was a statistically significant difference in HARM patterns among different subtypes (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001). LAA showed a significant association with the regional HARM pattern, compared with the other subgroups (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.002)</italic>.</p></table-wrap-foot></table-wrap>
<p>Table <xref ref-type="table" rid="T6">6</xref> shows the univariate associations between the clinical variables and the presence of HARM. All clinical variables were similar, and there were no statistically significant differences between the HARM-positive and -negative groups.</p>
<table-wrap position="float" id="T6">
<label>Table 6</label>
<caption><p>Relative HARM incidence of patients according to stroke location.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left" rowspan="2"/>
<th valign="top" align="left" rowspan="2">Total</th>
<th valign="top" align="center" colspan="2">HARM (&#x0002B;)<hr/></th>
<th valign="top" align="center" rowspan="2">HARM (&#x02212;)</th>
<th valign="top" align="center" colspan="4">Logistic regression<hr/></th>
</tr>
<tr>
<th valign="top" align="left">Regional</th>
<th valign="top" align="left">Randomized</th>
<th valign="top" align="center"><italic>p</italic>-Value</th>
<th valign="top" align="center">Odds ratio</th>
<th valign="top" align="center" colspan="2">CI</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" colspan="9"><bold>(A) Stroke location by vascular territories</bold></td>
</tr>
<tr>
<td align="left" valign="top">ICA</td>
<td align="left" valign="top">7 (2.61%)</td>
<td align="left" valign="top">2 (3.57%)</td>
<td align="left" valign="top">0 (0%)</td>
<td align="left" valign="top">5 (2.5%)</td>
<td align="center" valign="top">0.844</td>
<td align="center" valign="top">1.182</td>
<td align="center" valign="top">0.224</td>
<td align="center" valign="top">6.237</td>
</tr>
<tr>
<td align="left" valign="top">MCA</td>
<td align="left" valign="top">165 (61.57%)</td>
<td align="left" valign="top">41 (73.21%)</td>
<td align="left" valign="top">8 (66.67%)</td>
<td align="left" valign="top">116 (58%)</td>
<td align="center" valign="top">0.041</td>
<td align="center" valign="top">1.868</td>
<td align="center" valign="top">1.025</td>
<td align="center" valign="top">3.401</td>
</tr>
<tr>
<td align="left" valign="top">ACA</td>
<td align="left" valign="top">13 (4.85%)</td>
<td align="left" valign="top">3 (5.36%)</td>
<td align="left" valign="top">0 (0%)</td>
<td align="left" valign="top">10 (5%)</td>
<td align="center" valign="top">0.846</td>
<td align="center" valign="top">0.877</td>
<td align="center" valign="top">0.234</td>
<td align="center" valign="top">3.285</td>
</tr>
<tr>
<td align="left" valign="top">PCA</td>
<td align="left" valign="top">45 (16.79%)</td>
<td align="left" valign="top">12 (21.43%)</td>
<td align="left" valign="top">2 (16.67%)</td>
<td align="left" valign="top">31 (15.5%)</td>
<td align="center" valign="top">0.334</td>
<td align="center" valign="top">1.413</td>
<td align="center" valign="top">0.701</td>
<td align="center" valign="top">2.851</td>
</tr>
<tr>
<td align="left" valign="top">BA</td>
<td align="left" valign="top">37 (13.81%)</td>
<td align="left" valign="top">1 (1.79%)</td>
<td align="left" valign="top">0 (0%)</td>
<td align="left" valign="top">36 (18%)</td>
<td align="center" valign="top">0.009</td>
<td align="center" valign="top">0.068</td>
<td align="center" valign="top">0.009</td>
<td align="center" valign="top">0.506</td>
</tr>
<tr>
<td align="left" valign="top">VA</td>
<td align="left" valign="top">4 (1.49%)</td>
<td align="left" valign="top">0 (0%)</td>
<td align="left" valign="top">0 (0%)</td>
<td align="left" valign="top">4 (2%)</td>
<td align="center" valign="top">0.985</td>
<td align="center" valign="top">&#x0003C;0.001</td>
<td align="center" valign="top">&#x0003C;0.001</td>
<td align="center" valign="top">&#x0003E;999.999</td>
</tr>
<tr>
<td align="left" valign="top">SCA</td>
<td align="left" valign="top">5 (1.87%)</td>
<td align="left" valign="top">1 (1.79%)</td>
<td align="left" valign="top">0 (0%)</td>
<td align="left" valign="top">4 (2%)</td>
<td align="center" valign="top">0.781</td>
<td align="center" valign="top">0.731</td>
<td align="center" valign="top">0.080</td>
<td align="center" valign="top">6.659</td>
</tr>
<tr>
<td align="left" valign="top">AICA</td>
<td align="left" valign="top">3 (1.12%)</td>
<td align="left" valign="top">0 (0%)</td>
<td align="left" valign="top">0 (0%)</td>
<td align="left" valign="top">3 (1.5%)</td>
<td align="center" valign="top">0.987</td>
<td align="center" valign="top">&#x0003C;0.001</td>
<td align="center" valign="top">&#x0003C;0.001</td>
<td align="center" valign="top">&#x0003E;999.999</td>
</tr>
<tr>
<td align="left" valign="top">PICA</td>
<td align="left" valign="top">17 (6.34%)</td>
<td align="left" valign="top">3 (5.36%)</td>
<td align="left" valign="top">2 (16.67%)</td>
<td align="left" valign="top">12 (6%)</td>
<td align="center" valign="top">0.693</td>
<td align="center" valign="top">1.243</td>
<td align="center" valign="top">0.422</td>
<td align="center" valign="top">3.667</td>
</tr>
<tr>
<td align="left" valign="top">Border zone</td>
<td align="left" valign="top">8 (2.99%)</td>
<td align="left" valign="top">4 (7.14%)</td>
<td align="left" valign="top">0 (0%)</td>
<td align="left" valign="top">4 (2%)</td>
<td align="center" valign="top">0.121</td>
<td align="center" valign="top">3.063</td>
<td align="center" valign="top">0.744</td>
<td align="center" valign="top">12.598</td>
</tr>
<tr>
<td align="left" valign="top">Multiple</td>
<td align="left" valign="top">28 (10.45%)</td>
<td align="left" valign="top">9 (16.07%)</td>
<td align="left" valign="top">0 (0%)</td>
<td align="left" valign="top">19 (9.5%)</td>
<td align="center" valign="top">0.386</td>
<td align="center" valign="top">1.453</td>
<td align="center" valign="top">0.624</td>
<td align="center" valign="top">3.386</td>
</tr>
<tr>
<td align="left" valign="top" colspan="9"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2"/>
<td align="center" valign="top" rowspan="2"><bold>Total</bold></td>
<td align="center" valign="top" colspan="2"><bold>HARM (&#x0002B;)</bold><hr/></td>
<td align="center" valign="top" rowspan="2"><bold>HARM (&#x02212;)</bold></td>
<td align="center" valign="top" colspan="4"><bold>Logistic regression</bold><hr/></td>
</tr>
<tr>
<td align="left" valign="top"><bold>Regional</bold></td>
<td align="center" valign="top"><bold>Randomized</bold></td>
<td align="center" valign="top"><bold><italic>p</italic>-Value</bold></td>
<td align="center" valign="top"><bold>Odds ratio</bold></td>
<td align="center" valign="top" colspan="2"><bold>CI</bold></td>
</tr>
<tr>
<td align="left" valign="top" colspan="9"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" colspan="9"><bold>(B) Stroke location by anatomic compartments</bold></td>
</tr>
<tr>
<td align="left" valign="top">Cortex</td>
<td align="left" valign="top">122 (45.52%)</td>
<td align="left" valign="top">50 (89.29%)</td>
<td align="left" valign="top">6 (50%)</td>
<td align="left" valign="top">66 (33%)</td>
<td align="center" valign="top">&#x0003C;0.0001</td>
<td align="center" valign="top">9.475</td>
<td align="center" valign="top">4.754</td>
<td align="center" valign="top">18.883</td>
</tr>
<tr>
<td align="left" valign="top">CoronaR</td>
<td align="left" valign="top">86 (32.09%)</td>
<td align="left" valign="top">16 (28.57%)</td>
<td align="left" valign="top">5 (41.67%)</td>
<td align="left" valign="top">65 (32.5%)</td>
<td align="center" valign="top">0.805</td>
<td align="center" valign="top">0.928</td>
<td align="center" valign="top">0.513</td>
<td align="center" valign="top">1.680</td>
</tr>
<tr>
<td align="left" valign="top">BG&#x02009;&#x0002B;&#x02009;IC</td>
<td align="left" valign="top">89 (33.21%)</td>
<td align="left" valign="top">15 (26.79%)</td>
<td align="left" valign="top">4 (33.33%)</td>
<td align="left" valign="top">70 (35%)</td>
<td align="center" valign="top">0.287</td>
<td align="center" valign="top">0.720</td>
<td align="center" valign="top">0.394</td>
<td align="center" valign="top">1.318</td>
</tr>
<tr>
<td align="left" valign="top">Thalamus</td>
<td align="left" valign="top">30 (11.19%)</td>
<td align="left" valign="top">7 (12.5%)</td>
<td align="left" valign="top">1 (8.33%)</td>
<td align="left" valign="top">22 (11%)</td>
<td align="center" valign="top">0.863</td>
<td align="center" valign="top">1.079</td>
<td align="center" valign="top">0.456</td>
<td align="center" valign="top">2.551</td>
</tr>
<tr>
<td align="left" valign="top">Brainstem</td>
<td align="left" valign="top">32 (11.94%)</td>
<td align="left" valign="top">4 (7.14%)</td>
<td align="left" valign="top">0 (0%)</td>
<td align="left" valign="top">28 (14%)</td>
<td align="center" valign="top">0.084</td>
<td align="center" valign="top">0.384</td>
<td align="center" valign="top">0.130</td>
<td align="center" valign="top">1.138</td>
</tr>
<tr>
<td align="left" valign="top">Cerebellum</td>
<td align="left" valign="top">19 (7.09%)</td>
<td align="left" valign="top">3 (5.36%)</td>
<td align="left" valign="top">2 (16.67%)</td>
<td align="left" valign="top">14 (7%)</td>
<td align="center" valign="top">0.921</td>
<td align="center" valign="top">1.055</td>
<td align="center" valign="top">0.365</td>
<td align="center" valign="top">3.046</td>
</tr>
</tbody>
</table>
<table-wrap-foot><p><italic>HARM, hyperintense acute reperfusion marker; ICA, internal carotid artery; MCA, middle cerebral artery; ACA, anterior cerebral artery; PCA, posterior cerebral artery; BA, basilar artery; VA, vertebral artery; SCA, superior cerebellar artery; AICA, anterior inferior cerebellar artery; PICA, posterior inferior cerebellar artery; CI, confidence interval; coronaR, corona radiate; BG, basal ganglia; IC, internal capsule</italic>.</p>
<p><italic>Table shows the relative HARM incidence between the HARM-positive and -negative groups according to stroke location by the involved vascular territory and anatomic compartment</italic>.</p></table-wrap-foot></table-wrap>
</sec>
<sec id="S3-3">
<title>Relationship between HARM and Stroke Location with Respect to Vascular Territory and Anatomic Compartment</title>
<p>Table <xref ref-type="table" rid="T6">6</xref> shows the relative HARM incidence between the HARM-positive and -negative groups according to stroke location by the involved vascular territory and anatomic compartment. In terms of vascular territory, the relative HARM incidence in MCA and BA showed a statistically significant difference with <italic>p</italic>-values of 0.041 and 0.009, respectively. The OR for HARM from MCA infarction was 1.868 (95% CI: 1.025&#x02013;3.401) (Table <xref ref-type="table" rid="T6">6</xref>A), indicating that MCA infarction is associated with a higher incidence of HARM than infarction at other vascular territories. In contrast, the relative HARM incidence in BA showed a negative correlation with an OR of 0.068 (95% CI: 0.009&#x02013;0.506).</p>
<p>However, for different anatomic compartments, the OR for HARM from cortical infarction was 9.475 (95% CI: 4.754&#x02013;18.883) (Table <xref ref-type="table" rid="T6">6</xref>B), indicating that cortical infarction is associated with a significantly higher incidence of HARM than stroke in other anatomic compartments.</p>
</sec>
</sec>
<sec id="S4" sec-type="discussion">
<title>Discussion</title>
<p>In the current study, relative HARM incidence was significantly higher in the LAA subgroup than in the other subgroups (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.001), while the SVO subgroup showed a relatively lower HARM incidence compared with the other subgroups (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001). Although CE itself showed no statistically significant difference in HARM incidence compared with the other etiologic subgroups, the relative HARM incidence in the overall embolic infarctions, including the LAA and CE subgroups, was higher compared with that in the other subgroups (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001). In terms of stroke location, the relative HARM incidence in the MCA territorial infarction and cortical infarction subgroups was higher than that in other vascular and anatomic territories. These findings suggest that HARM on post-contrast FLAIR images is associated with specific stroke causes, especially embolic infarction.</p>
<p>HARM is well known to represent the BBB permeability in ischemic stroke patients (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>). Ischemic stroke evokes a marked biphasic opening of the BBB. Early opening of the BBB takes place within the first 30&#x02009;min of reperfusion and is followed by partial closing. The initial acute opening is described as a &#x0201C;hemodynamic&#x0201D; BBB opening resulting in cytotoxic edema (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>). Subsequently, a second delayed opening occurs 24&#x02013;48&#x02009;h later after reperfusion; this second opening results in vasogenic edema and is induced by &#x0201C;inflammation&#x0201D; (<xref ref-type="bibr" rid="B25">25</xref>). In the early opening phase, ischemic stroke restricts the delivery of oxygen and glucose to the brain tissue, which leads to a cascade of ischemic events and subsequent decrease in blood flow and ATP levels. Consequently, metabolic failure, ionic imbalance, and finally cellular death progresses within minutes (<xref ref-type="bibr" rid="B26">26</xref>). Following this, activated astrocytes and pericytes participate in the inflammatory cascade and release a number of substances that may be harmful to brain tissue (<xref ref-type="bibr" rid="B27">27</xref>). This wide variety of responses results in a number of effects including the loss of tight junctions between endothelial cells and finally results in the increase in BBB permeability (<xref ref-type="bibr" rid="B28">28</xref>).</p>
<p>We believe that HARM is more visible in the embolic infarctions, as compared with other TOAST subtypes, because of a lack of tolerance to the sudden hemodynamic changes in embolic infarction cases. High ischemic tolerance has been noted in atherosclerotic thromboembolic infarction rather than in embolic infarction and in old age patients rather than in young age stroke patients. Furthermore, the high recanalization rate in cardioembolic infarction is attributable to HARM incidence. In 4.7&#x02013;12% of cases, cardioembolic infarction showed a sudden onset of neurologic deficit followed by dramatic improvement of the initially severe neurologic symptoms. This may be due to distal migration of the embolus followed by recanalization of the occluded vessel (<xref ref-type="bibr" rid="B29">29</xref>). These sudden hemodynamic changes might contribute to the relatively higher incidence of the HARM in embolic infarction.</p>
<p>There are other findings to back up these theories in the current study. Within the LAA etiology group (<italic>n</italic>&#x02009;&#x0003D;&#x02009;75), 30 patients were HARM positive and the remaining 45 patients were HARM negative. We speculate that these results may be due to different pathophysiological mechanisms. The pathophysiological mechanisms of LAA have been proposed as (1) hypoperfusion of the involved vascular territory, (2) unstable plaque with artery-to-artery embolism, and (3) hypoperfusion-mediated microembolus formation. It is difficult to infer which mechanism may be responsible for an individual patient&#x02019;s condition in clinical practice (<xref ref-type="bibr" rid="B30">30</xref>). We hypothesized that the presence of HARM in acute stroke patients diagnosed with LAA etiology may be attributable to the artery-to-artery embolism, whereas the absence of HARM may be attributable to hypoperfusion.</p>
<p>Other studies have also found a higher incidence of HARM in MCA territorial infarction and cortical infarction compared to infarction at other vascular territories and anatomic compartments. Using high-resolution phase-contrast MRI, most of the IA blood flow was found to be distributed to the MCA (<xref ref-type="bibr" rid="B31">31</xref>). We hypothesized that the higher incidence of HARM in MCA territorial infarction may be attributable to the embolic stroke etiology in terms of IA flow dynamics. This result is in agreement with the findings of Garcia et al. (<xref ref-type="bibr" rid="B32">32</xref>), which show that most emboli lodge in the MCA distribution because 80% of the blood carried by large neck arteries flows through the MCA. Regarding stroke location according to the involved anatomic compartment, our study demonstrated a higher incidence of HARM with cortical infarction. This result is also in line with a previous study in which acute stroke lesions in the cortex and subcortical area were associated with CE and LAA infarction (<xref ref-type="bibr" rid="B33">33</xref>).</p>
<p>However, there were no significant differences in the relative HARM incidence between the CE subgroup itself and other etiologic subgroups, contrary to our priori hypothesis. This result could be explained by the relatively high proportion of &#x0201C;undetermined etiology&#x0201D; cases in the current study. Under the conventional TOAST classification, the presence of atrial fibrillation combined with other possible stroke etiologies belongs to the category of &#x0201C;undetermined etiology.&#x0201D; However, we speculated that the different histological compositions of the cardiac origin emboli and artery-to-artery emboli from large artery disease could have produced the differences in relative HARM incidence between artery-to-artery emboli and cardiogenic emboli. Emboli of cardiac origin are derived from blood stasis in the posterior left atrium and appendage and are mainly composed of fibrin and red blood cells (RBCs). In contrast, large artery-to-artery emboli are derived from atheromatous plaques in the aorta and carotid artery at the site of ulcerated plaque and are mainly composed of platelets and fibrin (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>). We hypothesized that large artery-to-artery emboli are more likely to induce BBB disruption compared to cardiac emboli, as RBC-rich emboli are promptly degraded by an intrinsic thrombolytic cascade. Notably, the composition of emboli may play a role in the success rate of thrombolysis with tPA since RBC-rich thrombi are known to be more vulnerable to thrombolysis compared to platelet-rich thrombi (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>).</p>
<p>In the current study, the majority of the SVO etiologic groups did not show HARM (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001). In a previous study, BBB dysfunction, indicated by IV injected contrast leakage, was demonstrated in white matter disease and dementia (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>), as well as in lacunar infarction (<xref ref-type="bibr" rid="B40">40</xref>). However, in the current study, BBB disruption, as indicated by HARM, was relatively low in the SVO etiologic group. In terms of our hypothesis that embolic sources of acute infarction cause more HARM than other stroke etiologies, our results are in line with that of a previous study, which demonstrated that cardiac or artery-to-artery embolism is unlikely to be a frequent cause of most lacunar strokes (<xref ref-type="bibr" rid="B41">41</xref>).</p>
<p>In contrast, among the SVO etiologic group (<italic>n</italic>&#x02009;&#x0003D;&#x02009;88), six patients showed HARM signs. This finding may be attributable to other causes or TIA rather than acute lacunar infarction itself. Recent studies have shown that TIA and imaging-negative strokes might be HARM positive and associated with focal BBB disruption (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B42">42</xref>). Lee et al. (<xref ref-type="bibr" rid="B43">43</xref>) suggested that a finding of HARM without diffusion abnormalities represents a specific type of TIA with favorable short-term neurologic outcomes, compared with imaging-negative stroke. The prevalence of SVO may be artifactually elevated to a misclassification of stroke subtypes (<xref ref-type="bibr" rid="B18">18</xref>). SVO usually presents as single subcortical infarction. Furthermore, recent studies have shown that single subcortical infarctions frequently are caused by branch occlusion associated with parental artery atherosclerotic plaque, arteriosclerotic proximal small vessel disease, or other embolic sources, rather than lipohyalinotic small artery disease (<xref ref-type="bibr" rid="B44">44</xref>).</p>
<p>We analyzed the topographic pattern of HARM with regard to stroke locations. Of the 67 patients in the HARM-positive group, 55 patients showed a linear cortical or sulcal enhancement along the same vascular territory near the acute infarction (regional pattern), whereas 12 patients showed ipsilateral or contralateral enhancement regardless of the acute infarction vascular territory (randomized pattern). Of note, LAA showed a significantly higher association with the regional HARM pattern relative to the other subgroups (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.002). Anatomically, the perivascular space is filled with interstitial fluid or CSF, encompassing the surface and penetrating the blood vessels of the brain. It has been demonstrated that systolic arterial pulsation is derived from CSF motion in the perivascular space (<xref ref-type="bibr" rid="B45">45</xref>). We speculate that this pulsatile CSF motion, termed &#x0201C;extracerebral CSF dynamic,&#x0201D; may influence the extent of contrast spillage indicated by the HARM pattern.</p>
<p>Blood&#x02013;brain barrier opening indicated by a HARM sign is distinct from enhancement of the leptomeninges (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B47">47</xref>) and from the parenchyma enhancement that is observed during the subacute stage of cerebral ischemia (<xref ref-type="bibr" rid="B48">48</xref>). A recent study reported that acute ischemic stroke patients with HARM showed a higher relative signal intensity compared with HARM-negative patients on FLAIR images in the adjacent brain parenchyma corresponding to the DWI-positive tissue, which is likely due to parenchymal enhancement (<xref ref-type="bibr" rid="B21">21</xref>). This result indicates that HARM does not only represent a contrast leakage from the pial system into the CSF space. However, it is not yet clear whether HARM is also associated with extravasation of contrast agent into the parenchyma.</p>
<p>In previous HARM studies, the commonly used gadolinium-containing contrast agents were Magnevist (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B49">49</xref>) or Gadovist (<xref ref-type="bibr" rid="B50">50</xref>). In the present study, we administered Gadovist at a dose of 0.2&#x02009;mmol/kg. Ostwaldt et al. (<xref ref-type="bibr" rid="B51">51</xref>) revealed that increasing the dosage of Gadobutrol is also associated with increased HARM incidence in acute stroke patients. Post-contrast FLAIR images obtained at 5&#x02009;min after contrast administration showed what was described as &#x0201C;early&#x0201D; HARM in a previous study (<xref ref-type="bibr" rid="B22">22</xref>). It should be emphasized that these &#x0201C;early HARM&#x0201D; signs are different from those of other previous studies in which HARM was depicted on follow-up unenhanced FLAIR images at 2&#x02013;48&#x02009;h after contrast administration in the initial MRI. In the current study, HARM was detected in 25.38% of acute ischemic strokes compared to the 5.5% reported by Lee et al. (<xref ref-type="bibr" rid="B22">22</xref>). This discrepancy might be attributable to the treatments applied before MRI image acquisition in the present study. In addition, the interval between symptom onset and MRI acquisition varied from 0&#x02009;h to 7&#x02009;days in the current study compared to 0&#x02013;24&#x02009;h in the study by Lee et al. (<xref ref-type="bibr" rid="B22">22</xref>). However, the incidence of HARM evaluated at 2&#x02013;48&#x02009;h after contrast administration was 33&#x02013;43% (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B50">50</xref>).</p>
<p>Although the HARM and risk of hemorrhagic transformation associated with sudden hemodynamic changes after carotid artery stenting or temporary balloon occlusion of the carotid artery have been widely studied in previous studies, there is little information on the relationship between the HARM and stroke etiology. The current study demonstrated that the HARM is associated with embolic infarction. This hypothesis is supported by our findings of a relatively higher incidence of the HARM in MCA and cortical infarction compared with infarction at other vascular territories and anatomic compartments. The results from this study may be translated into clinical practice and management, suggesting that evaluation of embolic sources needs to be done thoroughly, especially in HARM-positive strokes. It has been demonstrated that the HARM is not a specific radiologic finding in acute stroke and can be understood as a common finding in other BBB-disrupting conditions, such as postcarotid stent, postcardiac surgery, and traumatic brain injury (<xref ref-type="bibr" rid="B22">22</xref>). However, understanding the clinical significance of HARM signs in acute stroke and incorporating these findings into a stroke subtype classification scheme may be a rational approach for acute stroke treatment and prevention. Moreover, strict application of the conventional TOAST criteria could lead to categorization of the majority of strokes in the &#x0201C;undetermined etiology&#x0201D; category (<xref ref-type="bibr" rid="B52">52</xref>). Elucidating the most likely mechanism among coexisting potential stroke causes would therefore be useful. We expect that with the recent advances in stroke imaging, including the HARM on post-contrast FLAIR, it is possible to establish the correct classification of stroke.</p>
<p>With recent advancements in imaging, high-resolution MRIs can detect small plaques causing infarction, even in patients with normal vascular findings, which would not be classified as LAA etiology under previous classification systems (<xref ref-type="bibr" rid="B18">18</xref>). Despite the practical issues in using MRI for acute stroke evaluation, MRI can be useful for the accurate etiologic diagnosis of not only stroke but also stroke prognosis.</p>
<p>This study has a number of limitations. First, the sample population may be biased, as it is a retrospective single-center study from a single region. This cohort has relatively mild stroke with median NIHSS around 4&#x02013;5. Moreover, the distribution of stroke subtypes in our study showed a higher incidence of SVO than the population average in Korea (<xref ref-type="bibr" rid="B18">18</xref>). Second, symptom onset varied between the early hyper-acute (0&#x02013;6&#x02009;h), late hyper-acute (6&#x02013;24&#x02009;h), and acute (24&#x02009;h to 1&#x02009;week). The third drawback of this study is the limited evaluation of the most probable cause of stroke etiology in the undetermined group based on conventional TOAST classification. Numerous patients in the current study had a stroke of undetermined etiology, comprising up to 25%. Fourth, IV tPA and IA thrombolysis were performed in very few patients at varied timings; therefore, we could not identify the relationship between the HARM and applied treatments. Fifth, the infarct volume is not supplemented due to we included both single and multiple infarctions in this study. Further studies employing larger datasets with prospective study design and pathologic confirmation are needed to confirm the results in current study.</p>
<p>In conclusion, the presence of the HARM was significantly associated with embolic infarctions including LAA and CE. Conversely, SVO was exclusively associated with the absence of the HARM. Second, MCA and cortical infarction showed a more pronounced HARM compared to infarctions at other vascular territories and anatomic compartments. According to the results in the current study, we speculate that the presence of HARM on post-contrast FLAIR images was associated with specific stroke causes especially in embolic causes. However, future studies are required to confirm these preliminary findings and to determine if HARM can provide independent information on stroke causes.</p>
</sec>
<sec id="S5">
<title>Ethics Statement</title>
<p>This retrospective study was approved by our institutional review board. Informed consent was waived because only imaging findings and demographic data were retrieved from the picture archiving and communication system (PACS) server and medical records.</p>
</sec>
<sec id="S6" sec-type="author-contributor">
<title>Author Contributions</title>
<p>HC and H-GK collected the data and wrote the article. KL conceived and designed the study and wrote the article. EK, WC, BK, SH, and D-IC critically revised the article for important intellectual content.</p>
</sec>
<sec id="S7">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>The authors would to thank Su Jin Jeong of the Division of Biostatistics, Medical Science Research Institute, Kyung Hee University Medical Center for their statistical consulting services. The research was supported by a grant of the Basic Science Research Program through the Ministry of Education of the Republic of Korea (NRF-2016R1D1A1B03933173) and by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MSIP) (NRF-2017R1E1A2A02067113).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1"><label>1</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Hoyert</surname> <given-names>DL</given-names></name></person-group>. <source>75 Years of Mortality in the United States, 1935&#x02013;2010. NCHS Data Brief</source>. <publisher-loc>Hyattsville, MD</publisher-loc>: <publisher-name>National Center for Health Statistics</publisher-name> (<year>2012</year>). p. <fpage>1</fpage>&#x02013;<lpage>8</lpage>.</citation></ref>
<ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname> <given-names>K-S</given-names></name> <name><surname>Bang</surname> <given-names>OY</given-names></name> <name><surname>Kang</surname> <given-names>D-W</given-names></name> <name><surname>Yu</surname> <given-names>K-H</given-names></name> <name><surname>Bae</surname> <given-names>H-J</given-names></name> <name><surname>Lee</surname> <given-names>JS</given-names></name> <etal/></person-group> <article-title>Stroke statistics in Korea: part I. Epidemiology and risk factors: a report from the korean stroke society and clinical research center for stroke</article-title>. <source>J Stroke</source> (<year>2013</year>) <volume>15</volume>:<fpage>2</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.5853/jos.2013.15.1.2</pub-id><pub-id pub-id-type="pmid">24324935</pub-id></citation></ref>
<ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname> <given-names>H</given-names></name></person-group>. <article-title>Epidemiology of stroke: 2006 update</article-title>. <source>Korean J Stroke</source> (<year>2007</year>) <volume>9</volume>:<fpage>5</fpage>&#x02013;<lpage>10</lpage>.</citation></ref>
<ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petty</surname> <given-names>GW</given-names></name> <name><surname>Brown</surname> <given-names>RD</given-names></name> <name><surname>Whisnant</surname> <given-names>JP</given-names></name> <name><surname>Sicks</surname> <given-names>JD</given-names></name> <name><surname>O&#x02019;Fallon</surname> <given-names>WM</given-names></name> <name><surname>Wiebers</surname> <given-names>DO</given-names></name></person-group>. <article-title>Ischemic stroke subtypes a population-based study of functional outcome, survival, and recurrence</article-title>. <source>Stroke</source> (<year>2000</year>) <volume>31</volume>:<fpage>1062</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1161/01.STR.31.5.1062</pub-id><pub-id pub-id-type="pmid">10797166</pub-id></citation></ref>
<ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sprigg</surname> <given-names>N</given-names></name> <name><surname>Gray</surname> <given-names>LJ</given-names></name> <name><surname>Bath</surname> <given-names>PM</given-names></name> <name><surname>Lindenstr&#x000F8;m</surname> <given-names>E</given-names></name> <name><surname>Boysen</surname> <given-names>G</given-names></name> <name><surname>De Deyn</surname> <given-names>PP</given-names></name> <etal/></person-group> <article-title>Early recovery and functional outcome are related with causal stroke subtype: data from the tinzaparin in acute ischemic stroke trial</article-title>. <source>J Stroke Cerebrovasc Dis</source> (<year>2007</year>) <volume>16</volume>:<fpage>180</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2007.02.003</pub-id><pub-id pub-id-type="pmid">17689415</pub-id></citation></ref>
<ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname> <given-names>SW</given-names></name> <name><surname>Kim</surname> <given-names>SH</given-names></name> <name><surname>Lee</surname> <given-names>JY</given-names></name> <name><surname>Chu</surname> <given-names>CK</given-names></name> <name><surname>Yang</surname> <given-names>JH</given-names></name> <name><surname>Shin</surname> <given-names>HY</given-names></name> <etal/></person-group> <article-title>A new subtype classification of ischemic stroke based on treatment and etiologic mechanism</article-title>. <source>Eur Neurol</source> (<year>2006</year>) <volume>57</volume>:<fpage>96</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="doi">10.1159/000098059</pub-id></citation></ref>
<ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mohr</surname> <given-names>J</given-names></name> <name><surname>Caplan</surname> <given-names>LR</given-names></name> <name><surname>Melski</surname> <given-names>JW</given-names></name> <name><surname>Goldstein</surname> <given-names>RJ</given-names></name> <name><surname>Duncan</surname> <given-names>GW</given-names></name> <name><surname>Kistler</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>The Harvard Cooperative Stroke Registry: a prospective registry</article-title>. <source>Neurology</source> (<year>1978</year>) <volume>28</volume>:<fpage>754</fpage>&#x02013;<lpage>754</lpage>.<pub-id pub-id-type="doi">10.1212/WNL.28.8.754</pub-id><pub-id pub-id-type="pmid">567291</pub-id></citation></ref>
<ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sacco</surname> <given-names>RL</given-names></name> <name><surname>Ellenberg</surname> <given-names>J</given-names></name> <name><surname>Mohr</surname> <given-names>J</given-names></name> <name><surname>Tatemichi</surname> <given-names>T</given-names></name> <name><surname>Hier</surname> <given-names>D</given-names></name> <name><surname>Price</surname> <given-names>T</given-names></name> <etal/></person-group> <article-title>Infarcts of undetermined cause: the NINCDS Stroke Data Bank</article-title>. <source>Ann Neurol</source> (<year>1989</year>) <volume>25</volume>:<fpage>382</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1002/ana.410250410</pub-id><pub-id pub-id-type="pmid">2712533</pub-id></citation></ref>
<ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname> <given-names>HP</given-names></name> <name><surname>Bendixen</surname> <given-names>BH</given-names></name> <name><surname>Kappelle</surname> <given-names>LJ</given-names></name> <name><surname>Biller</surname> <given-names>J</given-names></name> <name><surname>Love</surname> <given-names>BB</given-names></name> <name><surname>Gordon</surname> <given-names>DL</given-names></name> <etal/></person-group> <article-title>Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment</article-title>. <source>Stroke</source> (<year>1993</year>) <volume>24</volume>:<fpage>35</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1161/01.STR.24.1.35</pub-id><pub-id pub-id-type="pmid">7678184</pub-id></citation></ref>
<ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>C</given-names></name> <name><surname>Kittner</surname> <given-names>S</given-names></name> <name><surname>McCarter</surname> <given-names>R</given-names></name> <name><surname>Sloan</surname> <given-names>M</given-names></name> <name><surname>Stern</surname> <given-names>B</given-names></name> <name><surname>Buchholz</surname> <given-names>D</given-names></name> <etal/></person-group> <article-title>Interrater reliability of an etiologic classification of ischemic stroke</article-title>. <source>Stroke</source> (<year>1995</year>) <volume>26</volume>:<fpage>46</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1161/01.STR.26.1.46</pub-id></citation></ref>
<ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ay</surname> <given-names>H</given-names></name> <name><surname>Furie</surname> <given-names>KL</given-names></name> <name><surname>Singhal</surname> <given-names>A</given-names></name> <name><surname>Smith</surname> <given-names>WS</given-names></name> <name><surname>Sorensen</surname> <given-names>AG</given-names></name> <name><surname>Koroshetz</surname> <given-names>WJ</given-names></name></person-group>. <article-title>An evidence-based causative classification system for acute ischemic stroke</article-title>. <source>Ann Neurol</source> (<year>2005</year>) <volume>58</volume>:<fpage>688</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="doi">10.1002/ana.20617</pub-id><pub-id pub-id-type="pmid">16240340</pub-id></citation></ref>
<ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amarenco</surname> <given-names>P</given-names></name> <name><surname>Bogousslavsky</surname> <given-names>J</given-names></name> <name><surname>Caplan</surname> <given-names>L</given-names></name> <name><surname>Donnan</surname> <given-names>G</given-names></name> <name><surname>Hennerici</surname> <given-names>M</given-names></name></person-group>. <article-title>New approach to stroke subtyping: the ASCO (phenotypic) classification of stroke</article-title>. <source>Cerebrovasc Dis</source> (<year>2009</year>) <volume>27</volume>:<fpage>502</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1159/000210433</pub-id></citation></ref>
<ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meschia</surname> <given-names>JF</given-names></name> <name><surname>Barrett</surname> <given-names>KM</given-names></name> <name><surname>Chukwudelunzu</surname> <given-names>F</given-names></name> <name><surname>Brown</surname> <given-names>WM</given-names></name> <name><surname>Case</surname> <given-names>LD</given-names></name> <name><surname>Kissela</surname> <given-names>BM</given-names></name> <etal/></person-group> <article-title>Interobserver agreement in the trial of org 10172 in acute stroke treatment classification of stroke based on retrospective medical record review</article-title>. <source>J Stroke Cerebrovasc Dis</source> (<year>2006</year>) <volume>15</volume>:<fpage>266</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2006.07.001</pub-id><pub-id pub-id-type="pmid">17904086</pub-id></citation></ref>
<ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname> <given-names>LB</given-names></name> <name><surname>Jones</surname> <given-names>MR</given-names></name> <name><surname>Matchar</surname> <given-names>DB</given-names></name> <name><surname>Edwards</surname> <given-names>LJ</given-names></name> <name><surname>Hoff</surname> <given-names>J</given-names></name> <name><surname>Chilukuri</surname> <given-names>V</given-names></name> <etal/></person-group> <article-title>Improving the reliability of stroke subgroup classification using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria</article-title>. <source>Stroke</source> (<year>2001</year>) <volume>32</volume>:<fpage>1091</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1161/01.STR.32.5.1091</pub-id><pub-id pub-id-type="pmid">11340215</pub-id></citation></ref>
<ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Atiya</surname> <given-names>M</given-names></name> <name><surname>Kurth</surname> <given-names>T</given-names></name> <name><surname>Berger</surname> <given-names>K</given-names></name> <name><surname>Buring</surname> <given-names>JE</given-names></name> <name><surname>Kase</surname> <given-names>CS</given-names></name></person-group>. <article-title>Interobserver agreement in the classification of stroke in the Women&#x02019;s Health Study</article-title>. <source>Stroke</source> (<year>2003</year>) <volume>34</volume>:<fpage>565</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1161/01.STR.0000054159.21017.7C</pub-id></citation></ref>
<ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Selvarajah</surname> <given-names>JR</given-names></name> <name><surname>Glaves</surname> <given-names>M</given-names></name> <name><surname>Wainwright</surname> <given-names>J</given-names></name> <name><surname>Jha</surname> <given-names>A</given-names></name> <name><surname>Vail</surname> <given-names>A</given-names></name> <name><surname>Tyrrell</surname> <given-names>PJ</given-names></name></person-group>. <article-title>Classification of minor stroke: intra-and inter-observer reliability</article-title>. <source>Cerebrovasc Dis</source> (<year>2009</year>) <volume>27</volume>:<fpage>209</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1159/000196817</pub-id><pub-id pub-id-type="pmid">19176952</pub-id></citation></ref>
<ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu Shang</surname> <given-names>W</given-names></name> <name><surname>Yan Liu</surname> <given-names>J</given-names></name></person-group>. <article-title>Stroke subtype classification: a comparative study of ASCO and modified TOAST</article-title>. <source>J Neurol Sci</source> (<year>2012</year>) <volume>314</volume>:<fpage>66</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1016/j.jns.2011.10.029</pub-id><pub-id pub-id-type="pmid">22118859</pub-id></citation></ref>
<ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>BJ</given-names></name> <name><surname>Kim</surname> <given-names>JS</given-names></name></person-group>. <article-title>Ischemic stroke subtype classification: an Asian viewpoint</article-title>. <source>J Stroke</source> (<year>2014</year>) <volume>16</volume>:<fpage>8</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="doi">10.5853/jos.2014.16.1.8</pub-id><pub-id pub-id-type="pmid">24741560</pub-id></citation></ref>
<ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>K&#x000F6;hrmann</surname> <given-names>M</given-names></name> <name><surname>Struffert</surname> <given-names>T</given-names></name> <name><surname>Frenzel</surname> <given-names>T</given-names></name> <name><surname>Schwab</surname> <given-names>S</given-names></name> <name><surname>Doerfler</surname> <given-names>A</given-names></name></person-group>. <article-title>The hyperintense acute reperfusion marker on fluid-attenuated inversion recovery magnetic resonance imaging is caused by gadolinium in the cerebrospinal fluid</article-title>. <source>Stroke</source> (<year>2012</year>) <volume>43</volume>:<fpage>259</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1161/STROKEAHA.111.632356</pub-id><pub-id pub-id-type="pmid">21980209</pub-id></citation></ref>
<ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warach</surname> <given-names>S</given-names></name> <name><surname>Latour</surname> <given-names>LL</given-names></name></person-group>. <article-title>Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood&#x02013;brain barrier disruption</article-title>. <source>Stroke</source> (<year>2004</year>) <volume>35</volume>:<fpage>2659</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1161/01.STR.0000144051.32131.09</pub-id></citation></ref>
<ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ostwaldt</surname> <given-names>A-C</given-names></name> <name><surname>Rozanski</surname> <given-names>M</given-names></name> <name><surname>Schmidt</surname> <given-names>WU</given-names></name> <name><surname>Nolte</surname> <given-names>CH</given-names></name> <name><surname>Hotter</surname> <given-names>B</given-names></name> <name><surname>Jungehuelsing</surname> <given-names>GJ</given-names></name> <etal/></person-group> <article-title>Early time course of FLAIR signal intensity differs between acute ischemic stroke patients with and without hyperintense acute reperfusion marker</article-title>. <source>Cerebrovasc Dis</source> (<year>2014</year>) <volume>37</volume>:<fpage>141</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1159/000357422</pub-id><pub-id pub-id-type="pmid">24481492</pub-id></citation></ref>
<ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>KM</given-names></name> <name><surname>Kim</surname> <given-names>JH</given-names></name> <name><surname>Kim</surname> <given-names>E</given-names></name> <name><surname>Choi</surname> <given-names>BS</given-names></name> <name><surname>Bae</surname> <given-names>YJ</given-names></name> <name><surname>Bae</surname> <given-names>H-J</given-names></name></person-group>. <article-title>Early stage of hyperintense acute reperfusion marker on contrast-enhanced FLAIR images in patients with acute stroke</article-title>. <source>AJR Am J Roentgenol</source> (<year>2016</year>) <volume>206</volume>:<fpage>1272</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.2214/AJR.15.14857</pub-id><pub-id pub-id-type="pmid">27010867</pub-id></citation></ref>
<ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname> <given-names>Z</given-names></name> <name><surname>Mathieson</surname> <given-names>G</given-names></name> <name><surname>Huttner</surname> <given-names>I</given-names></name></person-group>. <article-title>Blood-brain barrier opening to horseradish peroxidase in acute arterial hypertension</article-title>. <source>Acta Neuropathol</source> (<year>1979</year>) <volume>48</volume>:<fpage>45</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1007/BF00691790</pub-id><pub-id pub-id-type="pmid">506690</pub-id></citation></ref>
<ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuroiwa</surname> <given-names>T</given-names></name> <name><surname>Ting</surname> <given-names>P</given-names></name> <name><surname>Martinez</surname> <given-names>H</given-names></name> <name><surname>Klatzo</surname> <given-names>I</given-names></name></person-group>. <article-title>The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion</article-title>. <source>Acta Neuropathol</source> (<year>1985</year>) <volume>68</volume>:<fpage>122</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1007/BF00688633</pub-id><pub-id pub-id-type="pmid">3907257</pub-id></citation></ref>
<ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>ZG</given-names></name> <name><surname>Xue</surname> <given-names>D</given-names></name> <name><surname>Preston</surname> <given-names>E</given-names></name> <name><surname>Karbalai</surname> <given-names>H</given-names></name> <name><surname>Buchan</surname> <given-names>AM</given-names></name></person-group>. <article-title>Biphasic opening of the blood-brain barrier following transient focal ischemia: effects of hypothermia</article-title>. <source>Can J Neurol Sci</source> (<year>1999</year>) <volume>26</volume>:<fpage>298</fpage>&#x02013;<lpage>304</lpage>.<pub-id pub-id-type="doi">10.1017/S0317167100000421</pub-id><pub-id pub-id-type="pmid">10563216</pub-id></citation></ref>
<ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dirnagl</surname> <given-names>U</given-names></name></person-group>. <article-title>Pathobiology of injury after stroke: the neurovascular unit and beyond</article-title>. <source>Ann N Y Acad Sci</source> (<year>2012</year>) <volume>1268</volume>:<fpage>21</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06691.x</pub-id><pub-id pub-id-type="pmid">22994217</pub-id></citation></ref>
<ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Engelhardt</surname> <given-names>S</given-names></name> <name><surname>Patkar</surname> <given-names>S</given-names></name> <name><surname>Ogunshola</surname> <given-names>OO</given-names></name></person-group>. <article-title>Cell-specific blood-brain barrier regulation in health and disease: a focus on hypoxia</article-title>. <source>Br J Pharmacol</source> (<year>2014</year>) <volume>171</volume>:<fpage>1210</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1111/bph.12489</pub-id><pub-id pub-id-type="pmid">24641185</pub-id></citation></ref>
<ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lochhead</surname> <given-names>JJ</given-names></name> <name><surname>McCaffrey</surname> <given-names>G</given-names></name> <name><surname>Quigley</surname> <given-names>CE</given-names></name> <name><surname>Finch</surname> <given-names>J</given-names></name> <name><surname>DeMarco</surname> <given-names>KM</given-names></name> <name><surname>Nametz</surname> <given-names>N</given-names></name> <etal/></person-group> <article-title>Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation</article-title>. <source>J Cereb Blood Flow Metab</source> (<year>2010</year>) <volume>30</volume>:<fpage>1625</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1038/jcbfm.2010.29</pub-id><pub-id pub-id-type="pmid">20234382</pub-id></citation></ref>
<ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arboix</surname> <given-names>A</given-names></name> <name><surname>Alio</surname> <given-names>J</given-names></name></person-group>. <article-title>Acute cardioembolic cerebral infarction: answers to clinical questions</article-title>. <source>Curr Cardiol Rev</source> (<year>2012</year>) <volume>8</volume>:<fpage>54</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="doi">10.2174/157340312801215791</pub-id><pub-id pub-id-type="pmid">22845816</pub-id></citation></ref>
<ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>YP</given-names></name> <name><surname>Tan</surname> <given-names>L</given-names></name></person-group>. <article-title>The vulnerability of vessels involved in the role of embolism and hypoperfusion in the mechanisms of ischemic cerebrovascular diseases</article-title>. <source>Biomed Res Int</source> (<year>2016</year>) <volume>2016</volume>:<fpage>8531958</fpage>.<pub-id pub-id-type="doi">10.1155/2016/8531958</pub-id><pub-id pub-id-type="pmid">27314040</pub-id></citation></ref>
<ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zarrinkoob</surname> <given-names>L</given-names></name> <name><surname>Ambarki</surname> <given-names>K</given-names></name> <name><surname>W&#x000E5;hlin</surname> <given-names>A</given-names></name> <name><surname>Birgander</surname> <given-names>R</given-names></name> <name><surname>Eklund</surname> <given-names>A</given-names></name> <name><surname>Malm</surname> <given-names>J</given-names></name></person-group>. <article-title>Blood flow distribution in cerebral arteries</article-title>. <source>J Cereb Blood Flow Metab</source> (<year>2015</year>) <volume>35</volume>:<fpage>648</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1038/jcbfm.2014.241</pub-id></citation></ref>
<ref id="B32"><label>32</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Garcia</surname> <given-names>J</given-names></name> <name><surname>Khang-Loon</surname> <given-names>H</given-names></name> <name><surname>Pantoni</surname> <given-names>L</given-names></name></person-group>. <article-title>Pathology</article-title>. In: <person-group person-group-type="editor"><name><surname>Barnett</surname> <given-names>HJM</given-names></name> <name><surname>Mohr</surname> <given-names>JP</given-names></name> <name><surname>Stein</surname> <given-names>BM</given-names></name> <name><surname>Yatsu</surname> <given-names>FM</given-names></name></person-group>, editors. <source>Stroke Pathophysiology, Diagnosis and Management</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Churchill Livingston</publisher-name> (<year>1998</year>).</citation></ref>
<ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wessels</surname> <given-names>T</given-names></name> <name><surname>Wessels</surname> <given-names>C</given-names></name> <name><surname>Ellsiepen</surname> <given-names>A</given-names></name> <name><surname>Reuter</surname> <given-names>I</given-names></name> <name><surname>Trittmacher</surname> <given-names>S</given-names></name> <name><surname>Stolz</surname> <given-names>E</given-names></name> <etal/></person-group> <article-title>Contribution of diffusion-weighted imaging in determination of stroke etiology</article-title>. <source>AJNR Am J Neuroradiol</source> (<year>2006</year>) <volume>27</volume>:<fpage>35</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">16418352</pub-id></citation></ref>
<ref id="B34"><label>34</label><citation citation-type="journal"><collab>Women&#x02019;s Hospitals B</collab>. <article-title>Ischemic stroke: pathophysiology and principles of localization</article-title>. <source>Neurology</source> (<year>2009</year>) <volume>13</volume>:<fpage>1</fpage>.</citation></ref>
<ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jerjes-Sanchez</surname> <given-names>C</given-names></name></person-group>. <article-title>Venous and arterial thrombosis: a continuous spectrum of the same disease?</article-title> <source>Eur Heart J</source> (<year>2005</year>) <volume>26</volume>:<fpage>3</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1093/eurheartj/ehi041</pub-id></citation></ref>
<ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niessen</surname> <given-names>F</given-names></name> <name><surname>Hilger</surname> <given-names>T</given-names></name> <name><surname>Hoehn</surname> <given-names>M</given-names></name> <name><surname>Hossmann</surname> <given-names>K-A</given-names></name></person-group>. <article-title>Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke</article-title>. <source>Stroke</source> (<year>2003</year>) <volume>34</volume>:<fpage>2019</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1161/01.STR.0000080941.73934.30</pub-id><pub-id pub-id-type="pmid">12843350</pub-id></citation></ref>
<ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kirchhof</surname> <given-names>K</given-names></name> <name><surname>Welzel</surname> <given-names>T</given-names></name> <name><surname>Mecke</surname> <given-names>C</given-names></name> <name><surname>Zoubaa</surname> <given-names>S</given-names></name> <name><surname>Sartor</surname> <given-names>K</given-names></name></person-group>. <article-title>Differentiation of white, mixed, and red thrombi: value of CT in estimation of the prognosis of thrombolysis&#x02014;phantom study 1</article-title>. <source>Radiology</source> (<year>2003</year>) <volume>228</volume>:<fpage>126</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1148/radiol.2273020530</pub-id></citation></ref>
<ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wardlaw</surname> <given-names>J</given-names></name> <name><surname>Sandercock</surname> <given-names>P</given-names></name> <name><surname>Dennis</surname> <given-names>M</given-names></name> <name><surname>Starr</surname> <given-names>J</given-names></name></person-group>. <article-title>Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia?</article-title> <source>Stroke</source> (<year>2003</year>) <volume>34</volume>:<fpage>806</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1161/01.STR.0000058480.77236.B3</pub-id><pub-id pub-id-type="pmid">12624314</pub-id></citation></ref>
<ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wahlund</surname> <given-names>LO</given-names></name> <name><surname>Bronge</surname> <given-names>L</given-names></name></person-group>. <article-title>Contrast-enhanced MRI of White Matter Lesions in patients with blood-brain barrier dysfunction</article-title>. <source>Ann N Y Acad Sci</source> (<year>2000</year>) <volume>903</volume>:<fpage>477</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb06402.x</pub-id><pub-id pub-id-type="pmid">10818541</pub-id></citation></ref>
<ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>F&#x000F6;rster</surname> <given-names>A</given-names></name> <name><surname>Wenz</surname> <given-names>H</given-names></name> <name><surname>Groden</surname> <given-names>C</given-names></name></person-group>. <article-title>Hyperintense acute reperfusion marker on FLAIR in a patient with transient ischemic attack</article-title>. <source>Case Rep Radiol</source> (<year>2016</year>) <volume>2016</volume>:<fpage>9829823</fpage>.<pub-id pub-id-type="doi">10.1155/2016/9829823</pub-id><pub-id pub-id-type="pmid">27127673</pub-id></citation></ref>
<ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mead</surname> <given-names>G</given-names></name> <name><surname>Lewis</surname> <given-names>S</given-names></name> <name><surname>Wardlaw</surname> <given-names>J</given-names></name> <name><surname>Dennis</surname> <given-names>M</given-names></name> <name><surname>Warlow</surname> <given-names>C</given-names></name></person-group>. <article-title>Severe ipsilateral carotid stenosis and middle cerebral artery disease in lacunar ischaemic stroke: innocent bystanders?</article-title> <source>J Neurol</source> (<year>2002</year>) <volume>249</volume>:<fpage>266</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1007/s004150200003</pub-id><pub-id pub-id-type="pmid">11993524</pub-id></citation></ref>
<ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karageorgiou</surname> <given-names>E</given-names></name> <name><surname>Schwab</surname> <given-names>DJ</given-names></name> <name><surname>Ezzeddine</surname> <given-names>MA</given-names></name></person-group>. <article-title>FLAIR with contrast linked to better correlation with stroke symptoms than diffision-weighted imaging in a patient: detecting hyperintense acute reperfusion injury marker and cortical enhancement</article-title>. <source>Cerebrovasc Dis</source> (<year>2012</year>) <volume>34</volume>:<fpage>326</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1159/000342759</pub-id></citation></ref>
<ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>H</given-names></name> <name><surname>Kim</surname> <given-names>E</given-names></name> <name><surname>Lee</surname> <given-names>KM</given-names></name> <name><surname>Kim</surname> <given-names>JH</given-names></name> <name><surname>Bae</surname> <given-names>YJ</given-names></name> <name><surname>Choi</surname> <given-names>BS</given-names></name> <etal/></person-group> <article-title>Clinical implications of sulcal enhancement on postcontrast fluid attenuated inversion recovery images in patients with acute stroke symptoms</article-title>. <source>Korean J Radiol</source> (<year>2015</year>) <volume>16</volume>:<fpage>906</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.3348/kjr.2015.16.4.906</pub-id><pub-id pub-id-type="pmid">26175592</pub-id></citation></ref>
<ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>JS</given-names></name> <name><surname>Yoon</surname> <given-names>Y</given-names></name></person-group>. <article-title>Single subcortical infarction associated with parental arterial disease: important yet neglected sub-type of atherothrombotic stroke</article-title>. <source>Int J Stroke</source> (<year>2013</year>) <volume>8</volume>:<fpage>197</fpage>&#x02013;<lpage>203</lpage>.<pub-id pub-id-type="doi">10.1111/j.1747-4949.2012.00816.x</pub-id><pub-id pub-id-type="pmid">22568537</pub-id></citation></ref>
<ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linninger</surname> <given-names>AA</given-names></name> <name><surname>Tangen</surname> <given-names>K</given-names></name> <name><surname>Hsu</surname> <given-names>C-Y</given-names></name> <name><surname>Frim</surname> <given-names>D</given-names></name></person-group>. <article-title>Cerebrospinal fluid mechanics and its coupling to cerebrovascular dynamics</article-title>. <source>Annu Rev Fluid Mech</source> (<year>2016</year>) <volume>48</volume>:<fpage>219</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1146/annurev-fluid-122414-034321</pub-id></citation></ref>
<ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sze</surname> <given-names>G</given-names></name> <name><surname>Soletsky</surname> <given-names>S</given-names></name> <name><surname>Bronen</surname> <given-names>R</given-names></name> <name><surname>Krol</surname> <given-names>G</given-names></name></person-group>. <article-title>MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis</article-title>. <source>Am J Neuroradiol</source> (<year>1989</year>) <volume>10</volume>:<fpage>965</fpage>&#x02013;<lpage>75</lpage>.</citation></ref>
<ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Komiyama</surname> <given-names>M</given-names></name> <name><surname>Nakajima</surname> <given-names>H</given-names></name> <name><surname>Nishikawa</surname> <given-names>M</given-names></name> <name><surname>Yasui</surname> <given-names>T</given-names></name> <name><surname>Kitano</surname> <given-names>S</given-names></name> <name><surname>Sakamoto</surname> <given-names>H</given-names></name></person-group>. <article-title>Leptomeningeal contrast enhancement in moyamoya: its potential role in postoperative assessment of circulation through the bypass</article-title>. <source>Neuroradiology</source> (<year>2001</year>) <volume>43</volume>:<fpage>17</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1007/s002340000342</pub-id><pub-id pub-id-type="pmid">11214642</pub-id></citation></ref>
<ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imakita</surname> <given-names>S</given-names></name> <name><surname>Nishimura</surname> <given-names>T</given-names></name> <name><surname>Yamada</surname> <given-names>N</given-names></name> <name><surname>Naito</surname> <given-names>H</given-names></name> <name><surname>Takamiya</surname> <given-names>M</given-names></name> <name><surname>Yamada</surname> <given-names>Y</given-names></name> <etal/></person-group> <article-title>Magnetic resonance imaging of cerebral infarction: time course of Gd-DTPA enhancement and CT comparison</article-title>. <source>Neuroradiology</source> (<year>1988</year>) <volume>30</volume>:<fpage>372</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1007/BF00404100</pub-id><pub-id pub-id-type="pmid">3211311</pub-id></citation></ref>
<ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Latour</surname> <given-names>LL</given-names></name> <name><surname>Kang</surname> <given-names>DW</given-names></name> <name><surname>Ezzeddine</surname> <given-names>MA</given-names></name> <name><surname>Chalela</surname> <given-names>JA</given-names></name> <name><surname>Warach</surname> <given-names>S</given-names></name></person-group>. <article-title>Early blood&#x02013;brain barrier disruption in human focal brain ischemia</article-title>. <source>Ann Neurol</source> (<year>2004</year>) <volume>56</volume>:<fpage>468</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="doi">10.1002/ana.20199</pub-id></citation></ref>
<ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rozanski</surname> <given-names>M</given-names></name> <name><surname>Ebinger</surname> <given-names>M</given-names></name> <name><surname>Schmidt</surname> <given-names>WU</given-names></name> <name><surname>Hotter</surname> <given-names>B</given-names></name> <name><surname>Pittl</surname> <given-names>S</given-names></name> <name><surname>Heuschmann</surname> <given-names>PU</given-names></name> <etal/></person-group> <article-title>Hyperintense acute reperfusion marker on FLAIR is not associated with early haemorrhagic transformation in the elderly</article-title>. <source>Eur Radiol</source> (<year>2010</year>) <volume>20</volume>:<fpage>2990</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1007/s00330-010-1881-9</pub-id></citation></ref>
<ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ostwaldt</surname> <given-names>A-C</given-names></name> <name><surname>Rozanski</surname> <given-names>M</given-names></name> <name><surname>Schaefer</surname> <given-names>T</given-names></name> <name><surname>Ebinger</surname> <given-names>M</given-names></name> <name><surname>Jungeh&#x000FC;lsing</surname> <given-names>GJ</given-names></name> <name><surname>Villringer</surname> <given-names>K</given-names></name> <etal/></person-group> <article-title>Hyperintense acute reperfusion marker is associated with higher contrast agent dosage in acute ischaemic stroke</article-title>. <source>Eur Radiol</source> (<year>2015</year>) <volume>25</volume>:<fpage>3161</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1007/s00330-015-3749-5</pub-id><pub-id pub-id-type="pmid">25899419</pub-id></citation></ref>
<ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname> <given-names>M</given-names></name> <name><surname>Sauer</surname> <given-names>T</given-names></name> <name><surname>Alonso</surname> <given-names>A</given-names></name> <name><surname>Hennerici</surname> <given-names>M</given-names></name></person-group>. <article-title>Comparison of the new ASCO classification with the TOAST classification in a population with acute ischemic stroke</article-title>. <source>J Neurol</source> (<year>2012</year>) <volume>259</volume>:<fpage>1284</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1007/s00415-011-6325-1</pub-id><pub-id pub-id-type="pmid">22146904</pub-id></citation></ref>
</ref-list>
</back>
</article>